Substituted heteroaryls

Abstract

Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to substituted heteroaryls and more specifically to such compounds that are useful in the treatment of syndrome X (consisting of such abnormalities as obesity, dyslipidemia, hypercoagulation, hypertension, insulin resistance and leading to heart disease and diabetes), obesity, diabetes, immunological disease, bleeding disorders and/or cancer. More specifically, it relates to such compounds that are capable of inhibiting Protein tyrosine phosphatases (PTPs), in particular Protein tyrosine phosphatase-1B (PTP-1B) which is a negative regulator of the insulin and leptin signaling pathway and improves insulin-sensitivity.

2. Description of the Related Art

This invention relates to a class of heterocycle substituted carboxylic acids that are inhibitors of various PTPs, in particular PTP-1B.

Protein tyrosine phosphatases are a large family of transmembrane or intracellular enzymes that dephosphorylate substrates involved in a variety of regulatory processes (Fischer et al., 1991, Science 253:401-406). Protein tyrosine phosphatase-1B (PTP-1B) is an approximately 50 kd intracellular protein, which is present in abundant amounts in various human tissues (Charbonneau et al., 1989, Proc. Natl. Acad. Sci. USA 86:5252-5256; Goldstein, 1993, Receptor 3:1-15).

Determining which proteins are substrates of PTP-1B has been of considerable interest. One substrate which has aroused especial interest is the insulin receptor. The binding of insulin to its receptor results in autophosphorylation of the domain. This causes activation of the insulin receptor tyrosine kinase, which phosphorylates the various insulin receptor substrate (IRS) proteins that propagate the insulin signaling event further downstream to mediate insulin's various biological effects.

Seely et al., 1996, Diabetes 45:1379-1385 (“Seely”) studied the relationship of PTP-1B and the insulin receptor in vitro. Seely constructed a glutathione S-transferase (GST) fusion protein of PTP-1B that had a point mutation in the PTP-1B catalytic domain. Although catalytically inactive, this fusion protein was able to bind to the insulin receptor, as demonstrated by its ability to precipitate the insulin receptor from purified receptor preparations and from whole cell lysates derived from cells expressing the insulin receptor.

Ahmad et al., 1995, J. Biol. Chem. 270:20503-20508 used osmotic loading to introduce PTP-1B neutralizing antibodies into rat KRC-7 hepatoma cells. The presence of the antibody in the cells resulted in an increase of 42% and 38%, respectively, in insulin stimulated DNA synthesis and phosphatidyinositol 3′ kinase activity. Insulin receptor autophosphorylation and insulin receptor substrate-1 tyrosine phosphorylation were increased 2.2 and 2.0-fold, respectively, in the antibody-loaded cells. The antibody-loaded cells also showed a 57% increase in insulin stimulated insulin receptor kinase activity toward exogenous peptide substrates.

Kennedy et al., 1999, Science 283: 1544-1548 showed that protein tyrosine phosphatase PTP-1B is a negative regulator of the insulin signaling pathway, indicating that inhibitors of this enzyme are beneficial in the treatment of Type 2 diabetes, which appears to involve a defect in an early process in insulin signal transduction rather than a structural defect in the insulin receptor itself. (J. M. Olefsky, W. T. Garvey, R. R. Henry, D. Brillon, S. Matthai and G. R. Freidenberg, G. R. (1988).) Cellular mechanisms of insulin resistance in non-insulin-dependent (Type II) diabetes. (Am. J. Med. 85: Suppl. 5A, 86-105.) A drug that improved insulin sensitivity would have several advantages over traditional therapy of NIDDM using sulfonylureas, which do not alleviate insulin resistance but instead compensate by increasing insulin secretion.

Ragab et al (2003, J. Biol. Chem 278(42), 40923-32) showed that PTP 1B is involved in regulating platelet aggregation. Hence, inhibition of PTP 1B can be predicted to have an effect on bleeding disorder, and cardiovascular disease.

Romsicki et al., (2003, Arch Biochem. Biophys 414(1), 40-50) showed that TC PTP is structurally and functionally very similar. A PTP 1B inhibitor is very likely to also inhibit TC PTP. A knockout of the TC PTP gene produces a phenotype with impaired immune function. (You-Ten et al., 1997, J. Exp. Med. 186(5), 683-93). Hence, inhibitors of PTP 1B can be predict to inhibit TC PTP and modulate immune response.

It has also been demonstrated that PT-P1B is a negative regulator of leptin signaling (Kaszua et al. MolCell. Endocrinology, 195:109-118, 2002). PTP-1B deficient mice show enhanced potency for exogenous leptin to suppress food intake (Cheng, et al. Developmental Cell 2:497-503, 2002). Thus, inhibitors of PTP-1B augment the beneficial effects of leptin on food intake, body weight regulation and metabolism, in normal individuals and leptin resistant individuals.

Therefore, inhibitors of PTPs, and inhibitors of PTP-1B in particular, are useful in controlling or treating obesity, syndrome X, Type 2 diabetes, in improving glucose tolerance, and in improving insulin sensitivity in patients in need thereof. Such compounds are also useful in treating or controlling other PTP mediated diseases, such as the treatment of cancer, neurodegenerative diseases, immunological disorders, bleeding and cardiovascular disorders, and the like.

SUMMARY OF THE INVENTION

In a broad aspect, the invention encompasses the compounds of formula (I) shown below, pharmaceutical compositions containing the compounds and methods employing such compounds or compositions in the treatment of diabetes and/or cancer.

The invention provides compounds of formula I: and pharmaceutically acceptable salts thereof, wherein,

• • m is 0, 1, 2, 3, or 4,
  • p is 0, 1, 2, 3, 4, or 5;
  • ring A is an aryl, heterocycloalkyl or heteroaryl group;
  • L is a bond, —NH, or C₁-C₆ alkyl;
  • each R₄ is independently —H, halogen, C₁-C₆ alkyl, aryl, NH-heteroaryl, heteroaryl, —NH-aryl, heterocycloalkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —NO₂, wherein the aryl, heteroaryl, heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, —OH, —NH₂, —NO₂, oxo, —CN, halo, or —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, or
  • any two R₄ together with the carbon atoms to which they attached form an aryl, heteroaryl, or C₃-C₆ cycloalkyl, wherein the aryl, heteroaryl, cycloalkyl is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, —OH, —NH₂, —NO₂, oxo, —CN, halo, or —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁;
  • R₁₀ is —NR₁R₂, aryl, halogen, heteroaryl, —C(O)-heteroaryl, or heterocycloalkyl, wherein each of the aryl, heteroaryl, and heterocycloalkyl groups is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from the group consisting of oxo, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—NH—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ haloalkyl)-C(O)—OR₁, C₁-C₆ haloalkenyl-C(O)—OR₁, —C(O)—OR₁, —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃;
  • R₁ is H, C₁-C₆ alkyl, —(C₁-C₅ alkyl)-CO₂H, —(C₁-C₅ alkyl)-Si(C₁-C₅ alkyl)₃, —(C₁-C₅ alkyl)-CO₂—C₁-C₆ alkyl;
  • R₂ is phenyl optionally substituted with —(R₁₁)_n, wherein n is 1, 2, 3, 4, or 5, and R₁₁ is selected from alkyl, alkoxy, —SO₂NR₅R₆, —SO₂CF₃, —SO₂—(C₁-C₆ alkyl), thioalkoxy, haloalkyl, haloalkoxy, halothioalkoxy, —SO₂—(C₁-C₆ haloalkyl), —NR₇R₈, C₂-C₆ alkanoyl, —C(O)R₉, NO₂, C₁-C₆ alkoxycarbonyl;
  • R₅ and R₆ are independently H, C₁-C₆ alkyl, or C₂-C₆ alkanoyl wherein the alkyl and alkanoyl groups are optionally substituted with phenyl;
  • R₇ and R₈ are independently H, C₁-C₆ alkyl, C₂-C₆ alkanoyl;
  • R₉ is heterocycloalkyl, phenyl, —NH-phenyl, or —N(C₁-C₆ alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C₁-C₆ alkyl or NO₂; and
  • each R₃ is independently C₁-C₆ alkyl-aryl, C₁-C₆ alkyl-heteroaryl, aryl, heteroaryl, heterocycloalkyl, H, C₁-C₆ alkyl, halogen, C₁-C₄ alkoxy, —CN, —OH, —C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or —(C₁-C₄ alkoxy)-phenyl, wherein the aryl, heteroaryl, heterocycloalkyl and alkyl portions are optionally substituted with 1, 2, 3 or 4 groups that are independently selected from oxo, —NH₂, —OH, —SO₂—C₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, —C(O)—OR₁, or C₁-C₄-aryl.

The compounds of formula I bind to PTPS, and in particular to PTP-1B. The interaction with the enzyme, specifically PTP-1B, preferably results in inhibition of the enzyme.

The invention also includes intermediates that are useful in making the compounds of the invention.

The invention also provides pharmaceutical compositions comprising a compound or salt of formula I and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent.

The invention further provides methods of treating disease such as diabetes, syndrome X, cancer, immunological disease, bleeding disorders, or cardiovascular disease in a patient in need of such treatment, comprising administering to the patient a compound or pharmaceutically acceptable salt of formula I, or a pharmaceutical composition comprising a compound or salt of formula I.

In another aspect, the invention provides a method for inhibiting protein tyrosine phosphatases, preferably PTP-1B, comprising administering a therapeutically effective amount of a compound of formula I.

In another aspect, the invention provides a method for treating metabolic disorders related to insulin resistance or hyperglycemia, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula I.

The invention also provides the use of a compound or salt according to formula I for the manufacture of a medicament for use in treating diabetes or cancer or other diseases related to PTP.

The invention also provides methods of preparing the compounds of the invention and the intermediates used in those methods.

The invention also provides methods and compositions for combination therapy of Type I and Type II diabetes. In these embodiments, the invention provides formulations and pharmaceutical compositions, as well as methods for treating Type I and Type II diabetes with the compounds of formula I plus additional compounds and medicaments as disclosed in more detail below. In these embodiments, the methods of the invention can comprise treatment methods for Type I and Type II diabetes where the compounds of formula I are formulated with a therapeutically-effective amount of said additional compounds and medicaments. In alternative embodiments, treatment methods of the invention for Type I and Type II diabetes comprise administration of the inventive compounds of formula I as disclosed herein concomitantly, simultaneously or together with a therapeutically-effective amount of said additional compounds and medicaments.

DETAILED DESCRIPTION OF THE INVENTION

A preferred class of compounds of formula I are those wherein,

• • R₁₀ is halogen, quinoxalinyl, dihydroquinoxalinonyl, piperazinyl, tetrahydroquinolinyl, dihydroquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, indolyl, or isoindolyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently selected from the group consisting of —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), or phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃, and CO₂H.

More preferred compounds of formula I include those wherein each R₃ is independently C₁-C₆ alkyl, halogen, —(C₁-C₄ alkoxy)-phenyl; and each R₄ is independently halogen, or furan.

Still more preferred compounds of formula I include those wherein

• • R₁₀ is quinoxalinonyl, piperazinyl, tetrahydroquinolinyl, dihydroquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, indol-1-yl, or indol-2-yl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently selected from the group consisting of —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃, and CO₂H;
  • each R₃ is independently C₁-C₆ alkyl, halogen, or benzyloxy;
  • each R₄ is independently halogen.

Other preferred compounds of formula I include those of formula II: or a pharmaceutically acceptable salt thereof, wherein

• • m is 0, 1, 2, 3, or 4,
  • p is 0, 1, 2, 3, 4, or 5;
  • R₁₀ is —NR₁R₂, aryl, halogen, heteroaryl, or heterocycloalkyl, wherein each of the aryl, heteroaryl, and heterocycloalkyl groups is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from the group consisting of oxo, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—NH—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ haloalkyl)-C(O)—OR₁, C₁-C₆ haloalkenyl-C(O)—OR₁, —C(O)—OR₁, —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃;
  • R₁ is H, C₁-C₆ alkyl, —(C₁-C₅ alkyl)-CO₂H, —(C₁-C₅ alkyl)-CO₂—C₁-C₆ alkyl;
  • R₂ is phenyl optionally substituted with 1, 2, 3, 4, or 5 R₁₁, wherein R₁₁ is selected from alkyl, alkoxy, —SO₂NR₅R₆, —SO₂CF₃, —SO₂—(C₁-C₆ alkyl), thioalkoxy, haloalkyl, haloalkoxy, halothioalkoxy, —SO₂—(C₁-C₆ haloalkyl), —NR₇R₈, C₂-C₆ alkanoyl, —C(O)R₉, NO₂, C₁-C₆ alkoxycarbonyl;
  • R₅ and R₆ are independently H, C₁-C₆ alkyl, or C₂-C₆ alkanoyl wherein the alkyl and alkanoyl groups are optionally substituted with phenyl;
  • R₇ and R₈ are independently H, C₁-C₆ alkyl, C₂-C₆ alkanoyl;
  • R₉ is heterocycloalkyl, phenyl, —NH-phenyl, or —N(C₁-C₆ alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C₁-C₆ alkyl or NO₂,
  • each R₃ is independently C₁-C₆ alkyl, halogen, C₁-C₄ alkoxy, —CN, —OH, —C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or —(C₁-C₄ alkoxy)-phenyl, wherein the alkyl portions are optionally substituted with one or two groups that are independently selected from oxo, —NH₂, —OH, —SO₂—C₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, —C(O)—OR₁, or C₁-C₄-aryl; and
  • each R₄ is independently halogen, heterocycloalkyl, heteroaryl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —NO₂, wherein the heterocycloalkyl is optionally substituted with one or two groups independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, —OH, —NH₂, —NO₂, oxo, or —CN;
  • provided that when m is 1, R₄ is a Cl group attached to position 6 of the quinoxalinyl ring, p is 0 and R₃ is H, R₁₀ is not 3,4-dihydro-1H-quinoxalin-2-on-4-yl.

Preferred compound according to formula II are compounds wherein R₁₀ is halogen, quinoxalinyl, dihydroquinoxalinonyl, piperazinyl, tetrahydroquinolinyl, dihydroquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, indolyl, or isoindolyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently selected from the group consisting of oxo, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—NH—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ haloalkyl)-C(O)—OR₁, C₁-C₆ haloalkenyl-C(O)—OR₁, —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO_2, CF₃ and OCF₃, or CO₂H; and

Also preferred are compounds wherein R₁₀ is chloro, indolyl optionally substituted with one or two groups independently selected from halogen, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—NH—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ haloalkyl)-C(O)—OR₁, C₁-C₆ haloalkenyl-C(O)—OR₁. Preferably, the halogen is bromo or chloro. Preferably, R₁ is —H and the C₁-C₆ alkyl is —C₂H₄— or —CH₂—, C₁-C₆ haloalkyl is —CF₂—, and C₁-C₆ haloalkenyl is —CH═CF—.

Also preferred are compounds according to formula II, wherein each R₃ is independently C₁-C₆ alkyl, halogen, —CN, C₁-C₆-alkoxy, —(C₁-C₄ alkoxy)-phenyl; and each R₄ is independently halogen, or furanyl.

Also preferred are compound according to formula II, wherein R₁₀ is quinoxalinonyl, piperazinyl, tetrahydroquinolinyl, dihydroquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, or indol-1-yl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently selected from the group consisting of —C(O)—C₂H₄—C(O)—OH, —C(O)—NH—C₂H₄—C(O)—OH, —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃, and CO₂H;

• • each R₃ is independently C₁-C₆ alkyl, halogen, or benzyloxy;
  • each R₄ is independently halogen.

Preferably, in Formula II R₁₀ is indol-1-yl, indol-2-yl, isoindol-1-yl, or isoindol-2-yl, each of which is optionally substituted with 1 or 2 groups that are independently —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), or phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃, or CO₂H, and each R₃ is independently C₁-C₆ alkyl, halogen, or benzyloxy and each R₄ is independently halogen.

Preferably, R₁₀ In formula II is indol-1-yl or isoindol-2-yl, each of which is optionally substituted with 1 or 2 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₄ alkoxycarbonyl, or C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), and each R₃ is independently C₁-C₆ alkyl, halogen, or benzyloxy and each R₄ is independently halogen.

Preferably, R₁₀ in Formula II is indol-1-yl substituted with 1 or 2 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, or C₂-C₄ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl)

Preferably, in Formula II RIO is indol-1-yl substituted with 1 or 2 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, or C₂-C₄ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), where at least one group is an optionally substituted C₂-C₄ alkanoyl in the 3-position of the indole ring.

Still other preferred compounds of formula II include compounds of formula III wherein

• • m is 0, 1, 2, 3, or 4,
  • n is 0, 1, 2, 3, 4, or 5;
  • p is 0, 1, 2, 3, 4, or 5;
  • R₁ is H, C₁-C₆ alkyl, —(C₁-C₅ alkyl)-CO₂H, or —(C₁-C₅ alkyl)-CO₂—C₁-C₆ alkyl;
  • each R₃ is independently C₁-C₆ alkyl, halogen, or —(C₁-C₄ alkoxy)-phenyl; and
  • each R₄ is independently halogen, or heteroaryl;
  • each R₁₁ is independently —SO₂NR₅R₆, —SO₂CF₃, —SO₂CH₃, alkoxy, thioalkoxy, alkyl, haloalkyl, OCF₃, SCF₃, —NR₇R₈, C₂-C₆ alkanoyl, —C(O)R₉, NO₂, or C₁-C₆ alkoxycarbonyl;
    • wherein
    • R₅ and R₆ are independently H, C₁-C₆ alkyl, C₂-C₆ alkanoyl optionally substituted with phenyl;
    • R₇ and R₈ are independently H, C₁-C₆ alkyl, or C₂-C₆ alkanoyl; and
    • R₉ is phenyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, —NH-phenyl, or —N(C₁-C₆ alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C₁-C₆ alkyl, NO₂, or C₁-C₆ alkoxy.

Preferred compounds of formula III are compounds wherein

• • m is 0, 1, or 2;
  • n is 0, 1, or 2;
  • p is 0, 1, or 2; and
  • each R₁₁ is independently —SO₂NR₅R₆, —SO₂CF₃, —SO₂(C₁-C₆ alkyl), alkoxy, thioalkoxy, alkyl, haloalkyl, —SO₂(C₁-C₆ haloalkyl), OCF₃, SCF₃, —NR₇R₈, C₂-C₆ alkanoyl, NO_2, or C₁-C₆ alkoxycarbonyl.

Preferably, compound of formula III are compounds wherein each R₃ is independently C₁-C₆ alkyl, halogen, —(C₁-C₄ alkoxy)-phenyl; and each R₄ is independently halogen, or furan.

Also preferred are compound wherein n is 1 or 2, and R₁ is H or C₂-C₆ alkanoyl; and at least one of the R₁₁ groups is —SO₂NR₅R₆.

Also preferred are compound wherein n is 1 or 2; and one of the R₁₁ groups is —C(O)R₉, wherein R₉ is independently phenyl, piperidinyl, pyrrolidinyl, morpholinyl, —NH-phenyl, or —N(C₁-C₆ alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C₁-C₆ alkyl, NO₂, or C₁-C₆ alkoxy.

Still other preferred compounds of formula III include compounds of formula IV wherein

• • one of the R₁₁ groups is H and the other is C₁-C₆ alkyl.
  • the R₁₁ groups together with the carbon atoms to which they are attached form a group of the formula:

Preferably, the R₄ group is attached to position 6, of the quinazolinyl ring; and R₃ is H, C₁-C₆ alkyl, halogen, or benzyloxy.

Also preferred are compounds wherein

• • m is 0, 1, or 2;
  • n is 0, 1, or 2;
  • p is 0, 1, or 2; and
  • each R₁₁ is independently —SO₂NR₅R₆, —SO₂CF₃, —SO₂(C₁-C₆ alkyl), alkoxy, thioalkoxy, alkyl, haloalkyl, —SO₂(C₁-C₆ haloalkyl), OCF₃, SCF₃, —NR₇R₈, C₂-C₆ alkanoyl, NO₂, or C₁-C₆ alkoxycarbonyl.

Also preferred are compounds, wherein each R₃ is independently C₁-C₆ alkyl, halogen, —(C₁-C₄ alkoxy)-phenyl; and each R₄ is independently halogen or furanyl.

Also preferred are compounds wherein

• • n is 1 or 2;
  • R₁ is H or C₂-C₆ alkanoyl; and
  • at least one of the R₁₁ groups is —SO₂NR₅R₆.

Also preferred are compound wherein m is 1; the R₄ group is attached to position 6 of the quinazolinyl ring; and R₃ is H, C₁-C₆ alkyl, halogen, or benzyloxy. More preferably, R₄ is furanyl or halogen.

Still another preferred aspect of the compounds of formula I include compound according to formula: or a pharmaceutically acceptable salt thereof, wherein

• • m is 0, 1, 2, 3, or 4,
  • p is 0, 1, 2, 3, 4, or 5;
  • L is a bond or C₁-C₆ alkyl;
  • each R₄ is aryl, NH-heteroaryl, heteroaryl, —NH-aryl, heterocycloalkyl, wherein the aryl, heteroaryl, heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, —OH, —NH₂, —NO₂, oxo, —CN, halo, or —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, or
  • R₁₀ is —NR₁R₂, aryl, heteroaryl, —C(O)-heteroaryl, or heterocycloalkyl, wherein each of the aryl, heteroaryl, and heterocycloalkyl groups is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from the group consisting of oxo, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—NH—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—NH—OR₁, —C(OH)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ haloalkyl)-C(O)—OR₁, C₁-C₆ haloalkenyl-C(O)—OR₁, —C(O)—OR₁, —SO₂-(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃;
  • R₁ is H, C₁-C₆ alkyl, —(C₁-C₅ alkyl)-CO₂H, —(C₁-C₅ alkyl)-Si(C₁-C₅ alkyl)₃, —(C₁-C₅ alkyl)-CO₂—C₁-C₆ alkyl;
  • R₂ is phenyl optionally substituted with —(R₁₁)_n, wherein n is 1, 2, 3, 4, or 5, and R₁₁ is selected from alkyl, alkoxy, —SO₂NR₅R₆, —SO₂CF₃, —SO₂—(C₁-C₆ alkyl), thioalkoxy, haloalkyl, haloalkoxy, halothioalkoxy, —SO₂—(C₁-C₆ haloalkyl), —NR₇R₈, C₂-C₆ alkanoyl, —C(O)R₉, NO₂, C₁-C₆ alkoxycarbonyl;
  • R₅ and R₆ are independently H, C₁-C₆ alkyl, or C₂-C₆ alkanoyl wherein the alkyl and alkanoyl groups are optionally substituted with phenyl;
  • R₇ and R₈ are independently H, C₁-C₆ alkyl, C₂-C₆ alkanoyl;
  • R₉ is heterocycloalkyl, phenyl, —NH-phenyl, or —N(C₁-C₆ alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C₁-C₆ alkyl, or NO₂; and
  • each R₃ is independently C₁-C₆ alkyl-aryl, C₁-C₆ alkyl-heteroaryl, aryl, heteroaryl, heterocycloalkyl, —C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or —(C₁-C₄ alkoxy)-phenyl, wherein the aryl, heteroaryl, heterocycloalkyl and alkyl portions are optionally substituted with 1, 2, 3 or 4 groups that are independently selected from oxo, —NH₂, —OH, —SO₂—C₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, —C(O)—OR₁, or C₁-C₄-aryl.

In a preferred aspect, formula V includes compounds of formula VI or a pharmaceutically acceptable salt thereof, wherein

• • z represents an integer of from 1-5;
  • each R₁₁ independently carries the definition set forth above for Formula III;
  • L is a bond or C₁-C₆ alkyl;
  • R₄ is phenyl substituted with halogen; and
  • R₃ is aryl optionally substituted with 1, 2, 3 or 4 groups that are independently selected from C₁-C₆ alkyl or C₁-C₆ alkoxy.

In preferred compounds of Formula VI, z is 2 or 3; R₁₁ is H, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, amino; and n is 1 or 2. More preferably, z is 2; R₁₁ is halogen, particularly chloro or bromo and n is 1.

Preferably, L is a bond, R₃ is phenyl substituted with ethyl or methoxy, R₄ is phenyl substituted chloro or fluoro.

Still another preferred aspect of the compounds of formula I include compound according to formula: or a pharmaceutically acceptable salt thereof, wherein

• • m is 0, 1, 2, 3, or 4,
  • p is 0, 1, 2, 3, 4, or 5;
  • L is a bond, —NH, or C₁-C₆ alkyl;
  • each R₄ is aryl, NH-heteroaryl, heteroaryl, —NH-aryl, heterocycloalkyl, wherein the aryl, heteroaryl, heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, —OH, —NH₂, —NO₂, oxo, —CN, halo, or —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, or
  • R₁₀ is —NR₁R₂, aryl, heteroaryl, —C(O)-heteroaryl, or heterocycloalkyl, wherein each of the aryl, heteroaryl, and heterocycloalkyl groups is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from the group consisting of oxo, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—NH—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—NH—OR₁, —C(OH)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ haloalkyl)-C(O)—OR₁, C₁-C₆ haloalkenyl-C(O)—OR₁, —C(O)—OR₁, —SO₂-(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃;
  • R₁ is H, C₁-C₆ alkyl, —(C₁-C₅ alkyl)-CO₂H, —(C₁-C₅ alkyl)-Si(C₁-C₅ alkyl)₃, —(C₁-C₅ alkyl)-CO₂—C₁-C₆ alkyl;
  • R₂ is phenyl optionally substituted with —(R₁₁)_n, wherein n is 1, 2, 3, 4, or 5, and R₁₁ is selected from alkyl, alkoxy, —SO₂NR₅R₆, —SO₂CF₃, —SO₂—(C₁-C₆ alkyl), thioalkoxy, haloalkyl, haloalkoxy, halothioalkoxy, —SO₂—(C₁-C₆ haloalkyl), —NR₇R₈, C₂-C₆ alkanoyl, —C(O)R₉, NO₂, C₁-C₆ alkoxycarbonyl;
  • R₅ and R₆ are independently H, C₁-C₆ alkyl, or C₂-C₆ alkanoyl wherein the alkyl and alkanoyl groups are optionally substituted with phenyl;
  • R₇ and R₈ are independently H, C₁-C₆ alkyl, C₂-C₆ alkanoyl;
  • R₉ is heterocycloalkyl, phenyl, —NH-phenyl, or —N(C₁-C₆ alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C₁-C₆ alkyl, or NO₂; and
  • each R₃ is independently C₁-C₆ alkyl-aryl, C₁-C₆ alkyl-heteroaryl, aryl, heteroaryl, heterocycloalkyl, —C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or —(C₁-C₄ alkoxy)-phenyl, wherein the aryl, heteroaryl, heterocycloalkyl and alkyl portions are optionally substituted with 1, 2, 3 or 4 groups that are independently selected from oxo, —NH₂, —OH, —SO₂—C₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, —C(O)—OR₁, or C₁-C₄-aryl.

One aspect of formula VII include compounds of the formula or a pharmaceutically acceptable salt thereof, wherein

• • p is 0, 1 or 2;
  • L is a bond, —NH, or C₁-C₆ alkyl;
  • R₁ is H, —(C₁-C₅ alkyl)-Si(C₁-C₅ alkyl)₃ or C₁-C₆ alkyl;
  • R₄ is aryl optionally substituted with 1 or 2 groups that are independently selected from C₁-C₆ alkyl, or C₁-C₆ alkoxy;
  • R₁₀ is aryl or heteroaryl, wherein each of the aryl or heteroaryl groups is optionally substituted with 1 or 2 groups that are independently selected from the group consisting of —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or halogen; and
  • each R₃ is independently aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted with 1 or 2 groups that are independently selected from C₁-C₆ alkyl or C₁-C₆ alkoxy.

In one aspect of formula VIII, L is a bond and R₃ and R₄ is aryl substituted with C₁-C₆-alkoxy. Preferably, R₃ and R₄ are phenyl substituted with methoxy.

In another aspect of formula VIII, R₁₀ is heteroaryl substituted with two groups that are C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or halogen. Preferably, R₁₀ is indolyl wherein one substituent is halogen and the other is C(O)—(C₁-C₆ alkyl)-C(O)—OR₁. In another aspect, R₁ is —H or —(C₁-C₅ alkyl)-Si(C₁-C₅ alkyl)₃. Preferably, R₁—C₂H₅—Si—(CH₃)₃. In another aspect, the halogen is chloro or bromo.

Still another preferred aspect of the compounds of formula I include compound according to the formula: or a pharmaceutically acceptable salt thereof, wherein

• • m is 0, 1, 2, 3, or 4,
  • p is 0, 1, 2, 3, 4, or 5;
  • L is a bond, —NH, or C₁-C₆ alkyl;
  • each R₄ is aryl, NH-heteroaryl, heteroaryl, —NH-aryl, heterocycloalkyl, wherein the aryl, heteroaryl, heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, —OH, —NH₂, —NO₂, oxo, —CN, halo, or —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, or
  • R₁₀ is —NR₁R₂, aryl, heteroaryl, —C(O)-heteroaryl, or heterocycloalkyl, wherein each of the aryl, heteroaryl, and heterocycloalkyl groups is optionally substituted with 1, 2, 3, or 4 groups that are independently selected from the group consisting of oxo, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—NH—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—NH—OR₁, —C(OH)—(C₁-C₆ alkyl)-C(O)—OR₁, —C(O)—(C₁-C₆ haloalkyl)-C(O)—OR₁, C₁-C₆ haloalkenyl-C(O)—OR₁, —C(O)—OR₁, —SO₂—(C₁-C₆ alkyl), —SO₂-phenyl, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₂-C₆ alkanoyl optionally substituted with CO₂H or CO₂—(C₁-C₄ alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, CF₃ and OCF₃;
  • R₁ is H, C₁-C₆ alkyl, —(C₁-C₅ alkyl)-CO₂H, —(C₁-C₅ alkyl)-Si(C₁-C₅ alkyl)₃, —(C₁-C₅ alkyl)-CO₂—C₁-C₆ alkyl;
  • R₂ is phenyl optionally substituted with —(R₁₁)_n, wherein n is 1, 2, 3, 4, or 5, and R₁₁ is selected from alkyl, alkoxy, —SO₂NR₅R₆, —SO₂CF₃, —SO₂—(C₁-C₆ alkyl), thioalkoxy, haloalkyl, haloalkoxy, halothioalkoxy, —SO₂—(C₁-C₆ haloalkyl), —NR₇R₈, C₂-C₆ alkanoyl, —C(O)R₉, NO₂, C₁-C₆ alkoxycarbonyl;
  • R₅ and R₆ are independently H, C₁-C₆ alkyl, or C₂-C₆ alkanoyl wherein the alkyl and alkanoyl groups are optionally substituted with phenyl;
  • R₇ and R₈ are independently H, C₁-C₆ alkyl, C₂-C₆ alkanoyl;
  • R₉ is heterocycloalkyl, phenyl, —NH-phenyl, or —N(C₁-C₆ alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C₁-C₆ alkyl, or NO₂; and
  • each R₃ is independently C₁-C₆ alkyl-aryl, C₁-C₆ alkyl-heteroaryl, aryl, heteroaryl, heterocycloalkyl, —C(O)—OR₁, —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or —(C₁-C₄ alkoxy)-phenyl, wherein the aryl, heteroaryl, heterocycloalkyl and alkyl portions are optionally substituted with 1, 2, 3 or 4 groups that are independently selected from oxo, —NH₂, —OH, —SO₂—C₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, —C(O)—OR₁, or C₁-C₄-aryl.

One aspect of formula IX include compound according to the formula or a pharmaceutically acceptable salt thereof, wherein

• • p is 0, 1 or 2;
  • L is a bond or —NH—;
  • each R₄ is aryl or heteroaryl wherein the aryl and heteroaryl is optionally substituted with 1 or 2 groups that are independently selected from C₁-C₆ alkyl or C₁-C₆ alkoxy;
  • R₁₀ is aryl or heteroaryl wherein each of the aryl or heteroaryl groups is optionally substituted with 1 or 2 groups that are independently selected from the group consisting of —C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ or halogen;
  • R₁ is H or C₁-C₆ alkyl; and
  • each R₃ is independently aryl or heterocycloalkyl wherein the aryl and heterocycloalkyl portions are optionally substituted with 1 or 2 groups that are independently selected from C₁-C₆ alkyl or C₁-C₆ alkoxy.

In one aspect of formula X, R₄ is heterocycloalkyl and R₃ is heterocycloakyl or aryl substituted with C₁-C₆ alkyl. Preferably, R₄ is morpholino or pyrrolidinyl and R₃ is dihydroquinolinyl or phenyl substituted with tert-butyl. In another aspect, R₁₀ is heteroaryl substituted with 2 groups. Preferably, R₁₀ is indolyl wherein one substituent is C(O)—(C₁-C₆ alkyl)-C(O)—OR₁ and the other is halogen. Preferably, the R₁ is —H and th halogen is chloro or bromo.

In another aspect, the invention encompasses a method of treating diabetes comprising administering to a patient in need thereof, a pharmaceutically acceptable amount of a compound or salt of formulae I-X, or a pharmaceutical composition comprising a compound or salt of formulas I-X.

In another aspect, the invention encompasses a method of inhibiting TPT-1B comprising administering to a patient in need thereof, a pharmaceutically acceptable amount of a compound or salt of formulas I-X or a pharmaceutical composition comprising a compound or salt of formulas I-X.

In another aspect, the invention encompasses a pharmaceutical composition of a compound or salt of claim 1 and at least one pharmaceutically acceptable solvent, carrier, adjuvant or excipient.

In another aspect, the invention encompasses a method of treating cancer or neurodegenerative diseases comprising administering to a patient in need thereof, a pharmaceutically acceptable amount of a compound or salt of formulas I-X or a pharmaceutical composition comprising a compound or salt of formulas I-X.

The term “heterocycloalkyl,” refers to a ring or ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein said heteroatom is in a non-aromatic ring. The heterocycloalkyl ring is optionally fused to or otherwise attached to other heterocycloalkyl rings and/or non-aromatic hydrocarbon rings and/or phenyl rings. Preferred heterocycloalkyl groups have from 3 to 7 members. Examples of heterocycloalkyl groups include, for example, 1,2,3,4-tetrahydroisoquinolinyl, piperazinyl, morpholinyl, piperidinyl, tetrahydrofuranyl, pyrrolidinyl, pyridinonyl, and pyrazolidinyl. Preferred heterocycloalkyl groups include piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, pyridinonyl, dihydropyrrolidinyl, and pyrrolidinonyl.

The compounds of general Formula I may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier. One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques. In some cases such coatings may be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Formulations for oral use may also be presented as lozenges.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of general Formula I may also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.

Compounds of general Formula I may be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

For disorders of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base.

Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane. The transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The antiinflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

For administration to non-human animals, the composition may also be added to the animal feed or drinking water. It may be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It may also be convenient to present the composition as a premix for addition to the feed or drinking water. Preferred non-human animals include domesticated animals.

Methods of Preparation

The compounds of the present invention may be prepared by use of known chemical reactions and procedures. General methods for synthesizing the compounds are presented below. It is understood that the nature of the substituents required for the desired target compound often determines the preferred method of synthesis. All variable groups of these methods are as described in the generic description if they are not specifically defined below.

Certain compounds of the invention can be conveniently prepared from the corresponding substituted 2-aminobenzophenone as illustrated in Scheme A. In this method, the desired 2-aminobenzophenone, A-1, is conveniently treated with urea and an acid, preferably acetic acid, to form the cyclized condensation product, A-2. Subsequent activation of the urea moiety by conversion to vinyl chloride, A-3, with POCl₃ or PCl₅ followed by coupling to the desired amine, NHR₁R₂ (where NHR₁R₂ may be a cyclic amine such as, for example, piperidine, pyrrolidine, pyrrolidinone, indole, indoline or imidazolidine), gives the 2-aminoquinazoline, A-4. The specific coupling reaction conditions may depend on the substituents R_1-4 required for the desired target molecule. Often, the chloroquinazoline can simply be heated with the desired amine in a solvent like diphenylether, THF or DMF, or in the absence of solvent altogether.

For some molecules, a preferred method of synthesis may involve coupling the 2-aminobenzophenone with an isothiocyanate substituted with the desired R¹ substituent to form intermediate A-5. These reactions can often be performed simply by heating the two reagents is a suitable solvent. For some examples, the presence of a base like triethylamine, diisopropylethylamine, or pyridine will facilitate the reaction. The thiourea intermediate A-5, once formed, is treated with hydroxylamine to give the 2-aminoquinazoline oxide, A-6. Reduction, preferably with hydrogen gas using a palladium or nickel catalyst provides the desired 2-aminoquinazoline.

If the desired 2-aminobenzophenone is not commercially available, it can be prepared by a variety of known methods. One convenient method uses commercially available anthranilic acids as described in scheme B. In this method the anthranilic acid is treated with a reagent like acetic anhydride to form the activated intermediate B-2. Subsequent addition of an aryl or heteroaryl nucleophile, such as Grignard reagent B-3 provides the corresponding 2-aminobenzophenone derivative B-4.

Using an alternative method, the anthranilic acid can be treated with a reagent like carbonyldiimidazole (CDI), phosgene or triphosgene to form the corresponding anhydride B-5. Subsequent addition of methoxymethylamine forms the methoxymethyl amide commonly know as a Weinreb amide. Addition of an aryl or heteroaryl lithium reagent (2 equivalents) provides the desired 2-aminobenzophenone.

If the desired anthranilic acid is not commercially available it can be prepared by a variety of methods well known to those skilled in the art.

An alternative approach to make substituted 2-aminobenzophenones utilizes a benzyl nitrile and nitrobenzene derivative. As outlined in scheme C, treatment of nitrobenzene derivative C-1 and benzyl nitrile C-2 with a base like potassium hydroxide in ethanol gives the cyclized product C-3. Reduction of the benzoxisole with hydrogen in the presence of a palladium or nickel catalyst provides the desired 2-aminobenzophenone B-4. If a specific substituent is not stable to these reaction conditions, a variety of other reduction methods can be used. Some of them include iron and acetic acid, tin chloride and hydride reagents.

Another method for preparing compounds of the invention utilizes the chemistry outlined in scheme D below. Here a substituted anthranilic acid ester, D-1, is treated with potassium isocyanate followed by aqueous sodium hydroxide to give the corresponding quinazolinedione, D-2. Subsequent treatment with POCl₃ provides dichlorointermediate D-3. Selective coupling to the 4′-position gives monochloride D-4. This displacement can be carried out using a variety of methods depending on the particular product of interest. For examples of D-4 where X is a bond, the coupling reaction can be conveniently carried out using a transition metal catalyzed coupling reaction. Some examples include coupling an aryl or heteroarylboronic acid, tin or zinc reagent with a palladium catalyst.

For examples of D-4 where X is nitrogen, the substituted amine derivative can typically be introduced directly using a simple displacement reaction. When X is NR₁R₂, NR₁R₂ may be an aromatic amine, such as indole.

Once the R₂ substituent is in place, the 2-amino group can be introduced as previously described.

Another method for preparing compounds of the invention utilizes the chemistry outlined in scheme E below. Here the amino nitrile is reacted with carbon dioxide to form the quinazoline dione, which is then coupled to an R₄ group (in scheme E, R₄ is furanyl) via a transition metal catalyzed reaction. The resulting coupled product is treated with a chloride source to form the dichloro quinazoline, which is then selectively coupled via a transition metal catalyzed reaction to form the mono-chloro quinazoline product (wherein R₃ is CN). The mono-chloro quinazoline product is then treated with a variety of amines, including cyclic, acyclic, and aromatic amines, to form the desired final product.

Another method for preparing compounds of the invention utilizes the chemistry outlined in scheme F below. Here, the benzophenone is reacted with urea for form the quinazolinone prodct, which is then reacted with a chloride source to form the mono chloro quinazoline. The mono chloro quinazoline is then treated with an amine (here, 4-aminobenzenesulfonamide) to form the coupled product. The final product is then obtained by treating the coupled product with a transition metal catalyst and an appropriate R₄ group (here R₄ is furanyl.)

EXAMPLES

Example 1

Preparation of 2-Chloro-4,6-diphenylpyrimidine

A mixture of 2,4,6-Trichloropyrimidine, 2.76 g (15.0 mmol), phenylboronic acid, 3.66 g (30.0 mmol), Pd(OAc)₂, 86 mg (0.38 mmol), triphenylphosphine, 200 mg (0.76 mmol) in 150 mL of ethylene glycol dimethyl ether was heated to obtain a clear solution. To the solution was added 25 mL of 4.0M aq. Na₂CO₃. The reaction mixture was refluxed for 24 h at 70° C. The mixture was cooled to room temperature and diluted with 100 mL ethyl acetate. The organic layer was washed with water (2×50 mL), sat. aq. NaCl (1×50 mL), and dried (MgSO₄). After the solution was concentrated, the residue was recrystallized with Et₂O-Heptane (1:3) to afford the desired product in 1.64 g (41%) as a pale yellow solid. ¹H NMR (CDCl₃): δ 8.15-8.12 (m, 4H), 8.02 (s, 1H), 7.57-7.51 (m, 6H).

Example 2 (Compound No. 50)

Preparation of 4-{5-Bromo-1-[4-(4-butyl-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in Example 53, except 4-n-butylphenylmagnesium bromide and ZnCl₂ (1 mole equivalent) was used instead of 2-pyridylzinc bromide in step 5. In step 7 the reaction was acidified (2N HCl), diluted with H₂0 (10 mL) and the organics were extracted with EtOAc (3×25 mL). The concentrated oil was redissolved in a minimal amount THF and heptane was added until a yellow solid precipitated out. The solid was filtered and dried to give 4-{5-Bromo-1-[4-(4-butyl-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid: R_f 0.22 (Heptane/EtOAc, 3:2, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.09 (br s, 1H) 9.27 (s, 1H), 8.93 (d, J=9 Hz, 1H), 8.40-8.44 (m, 2H), 8.28 (d, J=2 Hz, 1H), 8.18 (d, J=9 Hz, 1H), 7.92 (d, J=8 Hz, 2H), 7.83 (d, J=2 Hz, 1H), 7.59 (dd, J=9, 2 Hz, 1H), 7.54 (d, J=8 Hz, 2H), 7.19 (d, J=3 Hz, 1H), 6.66 (dd, J=3, 2 Hz, 1H), 3.31 (t, J=6 Hz, 2H), 2.77 (t, J=7.5 Hz, 2H), 2.61 (t, J=6 Hz, 2H), 1.74-1.64 (m, 2H), 1.47-1.34 (m, 2H), 0.968 (t, J=7.5 Hz, 3H). ESI-LCMS m/z calcd for C₃₄H₂₈BrN₃O₄: 622.5; found 624.0 (M +1)⁺.

Example 3 (Compound No. 71)

Preparation of 4-{5-Bromo-1-[4-(1-carboxy-2-phenyl-ethylamino)-6-furan-2-yl-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in Example 64, except L-phenylalanine methyl ester was used instead of p-anisidine in step 5 to provide 4-{5-bromo-1-[4-(1-carboxy-2-phenyl-ethylamino)-6-furan-2-yl-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid as a brown solid: R_f 0.64 (CH₂Cl₂/MeOH, 12:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.19 (d, J=7.2 Hz, 1 H), 9.09 (s, 1 H), 8.90 (d, J=8.8 Hz, 1 H), 8.70 (d, J=1.8 Hz, 1 H), 8.38 (d, J=2.0 Hz, 1 H), 8.15 (dd, J=8.7, 2.0 Hz, 1 H), 7.86 (d, J=1.2 Hz, 1 H), 7.82 (d, J=8.7 Hz, 1 H), 7.53 (dd, J=8.7, 2.0 Hz, 1 H), 7.41 (d, J=7.3 Hz, 1 H), 7.24 (t, J=7.3 Hz, 2 H), 7.13 (t, J=7.3 Hz, 2 H), 7.08 (d, J=3.4 Hz, 1 H), 6.68 (dd, J=3.4, 1.2 Hz, 1 H), 5.00 (q, J=7.2 Hz, 1 H), 3.38 (d, J=7.2 Hz, 1 H), 3.27 (t, J=6.4 Hz, 2 H), 2.63 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₃₃H₂₅BrN₄O₆: 652.1; found 653.0 (M+1)⁺.

Example 4 (Compound No. 72)

Preparation of 4-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperazine-1-carboxylic acid tert-butyl ester

This compound was prepared in a manner analogous to that set forth in Example 64, except piperazine-1-carboxylic acid tert-butyl ester was used instead of p-anisidine in step 5 to provide 4-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperazine-1-carboxylic acid tert-butyl ester (0.40 g, 41%): R_f 0.34 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 9.14 (s, 1H), 8.88 (d, J=9 Hz, 1H) 8.34 (d, J=2 Hz, 1H), 8.20-8.17 (m, 2H), 7.92 (d, J=9 Hz, 1H), 7.82 (d, J=2 Hz, 1H), 7.56 (dd, J=9, 2 Hz, 1H), 7.16 (d, J=3 Hz, 1H), 6.65 (dd, J=3, 2 Hz, 1H), 4.01 (m, 4H), 3.67 (m, 4H), 3.29 (t, J=6 Hz, 2H), 2.61 (t, J=6 Hz, 2H), 1.45 (s, 9H). ESI-LCMS m/z calcd for C₃₃H₃₂BrN₅O₆: 674.5; found 676.0 (M+1)⁺.

Example 5 (Compound No. 120)

4-[5-Chloro-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid 2-trimethylsilanylethyl ester

A mixture of 2-chloro-4,6-diphenylpyrimidine, 250 mg (0.94 mmol), 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester, 380 mg (1.03 mmol), K₂CO₃ 260 mg (1.87 mmol), and N,N-dimethylaminopyridine, 11 mg (0.09 mmol) in 20 mL DMSO was heated to 80° C. for 6 h. The mixture was cooled to room temperature and diluted with 100 mL of EtOAc. The mixture was washed with sat. aq. LiCl (3×100 mL), water (3×100 mL), sat. aq. NaCl (1×φmL), and dried (MgSO₄). After the solution was concentrated, the residue was purified via column chromatography (eluted with 10% EtOAc-heptane) to afford the desired product in 0.47 g (88%) as a pale yellow solid. ¹H NMR (DMSO-d₆): δ 9.39 (s, 1H), 8.87 (d, 1H, J=9.7 Hz), 8.56 (s, 1H), 8.51-8.48 (m, 3H), 8.26 (d, 1H, J=2.7 Hz), 7.64-7.62 (m, 5H), 7.52 (dd, 1H, 9.7, 2.7 Hz), 4.10 (dd, 2H, J=9.0, 9.0 Hz), 3.40 (t, 2H, J=7.2 Hz), 2.67 (t, 2H, J=7.2 Hz), 0.94 (dd, 2H, J=9.0, 9.0 Hz), 0.00 (s, 9H).

Example 6 (Compound 95)

Preparation of 4-{5-Bromo-1-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-6-pyrrolidin-1-yl-[1,3,5]-triazin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid

A solution of 4-(5-bromo-1H-indol-3-yl)-4-oxobutyric acid (148 mg, 0.5 mmol) in anhydrous dimethylformamide (5 mL) was added dropwise to a stirred suspension of sodium hydride (95%, 50 mg, 2.0 mmol) in dimethylformamide (5 mL). After 30 mins, a solution of 1-(4-chloro-6-tetrahydro-1H-pyroll-1-yl-[1,3,5]-triazin-2-yl)-1,2,3,4-tetrahydroquinoline (158 mg, 0.5 mmol) in dimethylformamide (5 mL) was added dropwise. The reaction mixture was stirred at 70° C. for 16 hours, cooled to room temperature and then poured carefully into water (20 mL), acidified to pH 4 with 0.5N hydrochloric acid and extracted with ethyl acetate (3×25 mL). The combined extract was washed with water, brine, dried over anhydrous MgSO₄, filtered and concentrated in vacuo. Purification by flash column chromatography (5% methanol in dichloromethane) afforded the title compound as a white solid (221 mg, 77%), R_f: 0.30 (10% methanol in dichloromethane); 1H NMR (THF-d8, 300 MHz) δ 8.78 (1H, s, ArH), 8.43 (1H, d, J=9 Hz, ArH), 8.36 (1H, d, J=2 Hz, ArH), 7.77 (1H, d, J=9 Hz, ArH), 7.20 (1H, dd, J=9, 2 Hz, ArH), 7.08 (1H, t, J=7 Hz, ArH), 7.02 (1H, d, J=7 Hz), 6.92 (1H, t, J=7 Hz, Ar—H), 3.98 (2H, t, J=6 Hz, CH₂N), 3.45 (4H, br s, 2×CH₂N), 3.06 (2H, t, J=6 Hz, CH₂CO), 2.78 (1H, s, CHHN), 2.72 (2H, t, J=7 Hz, CH₂CO), 2.64 (1H, s, CHHN), 2.56 (2H, t, J=7 Hz, CH₂), 1.92 (4H, m, CH₂CH₂); ESI-LCMS e/z calculated for C₂₈H₂₇BrN₆O₃ 575.464, found 575 [M+H (⁷⁹Br)]⁺, 577 [M+H (⁸¹Br)]⁺, 597 [M+Na (⁷⁹Br)]⁺, 599 [M+Na (⁸¹Br)]⁺.

Example 7

The following compounds are prepared essentially according to the procedures described in the schemes, charts, examples and preparations set forth herein.

These compounds were named using ChemDraw v. 6.02, which is sold by Cambridgesoft.com in Cambridge, Mass., or using Name Pro IUPAC Naming Software, version 5.09, available from Advanced Chemical Development, Inc., 90 Adelaide Street West, Toronto, Ontario, M5H 3V9, Canada.

Compound
No.	Structure	Name
1		4-(6-Bromo-4-phenyl- quinazolin-2-ylamino)- benzenesulfonamide
2		4-(6-Chloro-4-phenyl- quinazolin-2-ylamino)- benzenesulfonamide
3		4-[4-(4-tert-Butyl- phenyl)-quinazolin-2- ylamino]- benzenesulfonamide
4		2-{[4-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		benzenesulfonyl]-methyl-
		amino}-3-phenyl-propionic
		acid
5		2-({4-[(6-Bromo-4-phenyl- quinazolin-2-yl)- carboxymethyl-amino]- benzenesulfonyl}-methyl- amino)-3-phenyl-propionic acid
6		[(6-Bromo-4-phenyl-
		quinazolin-2-yl)-(4-
		sulfamoyl-phenyl)-amino]-
		acetic acid
7		2-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		benzenesulfonamide
8		4-[(6-Bromo-4-phenyl-
		quinazolin-2-yl)-(4-
		sulfamoyl-phenyl)-amino]-
		butyric acid
9		(6-Bromo-4-phenyl- quinazolin-2-yl)-(4- trifluoromethylsulfanyl- phenyl)-amine
10		3-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		benzenesulfonamide
11		(6-Bromo-4-phenyl- quinazolin-2-yl)-(4- trifluoromethanesulfonyl- phenyl)-amine
12		4-(6-Chloro-4-phenyl- quinazolin-2-yl)-3,4- dihydro-1H-quinoxalin-2- one
13		N-[4-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		phenyl]-acetamide
14		1-[4-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		phenyl]-ethanone
15		[3-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		phenyl]-piperidin-1-yl-
		methanone
16		[3-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		phenyl]-morpholin-4-yl-
		methanone
17		(6-Chloro-4-phenyl-
		quinazolin-2-yl)-(4-nitro-
		phenyl)-amine
18		6-chloro-N-(1,1- dioxido-1-benzothien-6- yl)-4-phenylquinazolin-2- amine
19		2-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-3-
		phenyl-propionic acid
20		2-[6-Bromo-4-(4-butyl-
		phenyl)-quinazolin-2-
		ylamino]-
		benzenesulfonamide
21		4-(6-Furan-2-yl-4-phenyl- quinazolin-2-ylamino)- benzenesulfonamide
22		4-(6-Chloro-4-phenyl-
		quinazolin-2-ylamino)-
		benzoic acid methyl ester
23		N-(2,4-Dimethyl-phenyl)-4-
		(6-methyl-4-phenyl-
		quinazolin-2-ylamino)-
		benzamide
24		4-(6-Bromo-4-phenyl- quinazolin-2-yl)- piperazine-1-carboxylic acid tert-butyl ester
25		[4-(6-Bromo-4-phenyl-
		quinazolin-2-ylamino)-
		phenyl]-piperidin-1-yl-
		methanone
26		4-(6-Bromo-4-phenyl- quinazolin-2-ylamino)-N- (2,6-dimethyl-phenyl)- benzamide
27		(6-Bromo-4-phenyl-
		quinazolin-2-yl)-(4-nitro-
		phenyl)-amine
28		(6-Bromo-4-phenyl-
		quinazolin-2-yl)-(2-
		methyl-5-nitro-phenyl)-
		amine
29		4-[4-(4-Butyl-phenyl)-6- furan-2-yl-quinazolin-2- ylamino]- benzenesulfonamide
30		[6-Chloro-4-(4-ethyl-
		phenyl)-quinazolin-2-yl]-
		(4-nitro-phenyl)-amine
31		4-(4-Benzyloxy-phenyl)-6- bromo-2-chloro-quinazoline
32		2-(4-Benzenesulfonyl- piperazin-1-yl)-6-chloro- 4-phenyl-quinazoline
33		6-Chloro-2-(3,4-dihydro- 2H-quinolin-1-yl)-4-(4- ethyl-phenyl)-quinazoline
34		(6-Chloro-4-phenyl-
		quinazolin-2-yl)-(2-nitro-
		phenyl)-amine
35		2-(6-Furan-2-yl-4-phenyl-
		quinazolin-2-ylamino)-
		benzenesulfonamide
36		[(6-Chloro-4-phenyl-
		quinazolin-2-yl)-(2-nitro-
		phenyl)-amino]-acetic acid
		ethyl ester
37		1-(6-Chloro-4-phenyl-
		quinazolin-2-yl)-1H-
		indole-5-carboxylic acid
		methyl ester
38		6-Chloro-2-[4-(4-nitro- phenyl)-piperazin-1-yl]-4- phenyl-quinazoline
39		4-[1-(6-Chloro-4-phenyl- quinazolin-2-yl)-1H-indol- 3-yl]-4-oxo-butyric acid
40		4-[5-Bromo-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
41		4-[5-Bromo-1-(6-fluoro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
42		4-{1-[6-Bromo-4-(2-fluoro-
		phenyl)-quinazolin-2-yl]-
		1H-indol-3-yl}-4-oxo-
		butyric acid
43		4-{5-Bromo-1-[6-furan-2-
		yl-4-(4-methoxy-phenyl)-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
44		4-{5-Bromo-1-[4-(4-cyano-
		phenyl)-6-furan-2-yl-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
45		4-{5-Bromo-1-[4-(4-fluoro-
		phenyl)-6-furan-2-yl-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
46		4-[1-(6-Chloro-4-phenyl-
		quinazolin-2-yl)-6-fluoro-
		1H-indol-3-yl]-4-oxo-
		butyric acid
47		4-[1-(6-Furan-2-yl-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
48		4-[5-Bromo-1-(6-furan-2-
		yl-4-phenyl-quinazolin-2-
		yl)-1H-indol-3-yl]-4-oxo-
		butyric acid
49		4-{1-[4-(4-Butyl-phenyl)-
		6-furan-2-yl-quinazolin-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
50		4-{5-Bromo-1-[4-(4-butyl- phenyl)-6-furan-2-yl- quinazolin-2-yl]-1H-indol- 3-yl}-4-oxo-butyric acid
51		4-[5-Chloro-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
52		4-[5-Bromo-1-(6-chloro-4-
		phenyl-quinolin-2-yl)-1H-
		indol-3-yl]-4-oxo-butyric acid
53		4-[5-Bromo-1-(6-furan-2-
		yl-4-pyridin-2-yl-
		quinazolin-2-yl)-1H-indol-
		3-yl]-4-oxo-butyric acid
54		4-[5-Chloro-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-4-hydroxy-
		butyric acid
55		{[5-Chloro-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indole-3-carbonyl]-
		amino}-acetic acid
56		3-(3-Carboxy-propionyl)-1-
		(6-chloro-4-phenyl-
		quinazolin-2-yl)-1H-
		indole-5-carboxylic acid
		methyl ester
57		4-[5-Chloro-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-N-hydroxy-
		4-oxo-butyramide
58		3-{[5-Chloro-1-(6-chloro-
		4-phenyl-quinazolin-2-yl)-
		1H-indole-3-carbonyl]-
		amino}-propionic acid
59		3-[5-Chloro-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-3-hydroxy-
		propionic acid
60		3-[5-Chloro-1-(6-chloro-4- phenyl-quinazolin-2-yl- 1H-indol-3-yl]-2,2- difluoro-3-oxo-propionic acid
61		3-[5-Chloro-1-(6-chloro-4- phenyl-quinazolin-2-yl- 1H-indol-3-yl]-2-fluoro- acrylic acid
62		3-[5-Chloro-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-3-oxo-
		propionic acid
63		4-[6-Chloro-1-(6-chloro-4-
		phenyl-quinazolin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
64		4-{5-Bromo-1-[6-furan-2-
		yl-4-(4-methoxy-
		phenylamino)-quinazolin-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
65		4-{5-Bromo-1-[6-furan-2-
		yl-4-(4-methoxy-
		benzylamino)-quinazolin-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
66		4-(5-Bromo-1-{6-furan-2-
		yl-4-[(furan-2-ylmethyl)-
		amino]-quinazolin-2-yl}-
		1H-indol-3-yl)-4-oxo-
		butyric acid
67		4-{5-Chloro-1-[4-(4-
		fluoro-benzylamino)-6-
		furan-2-yl-quinazolin-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
68		4-[5-Chloro-1-(6-furan-2-
		yl-4-pyridin-2-yl-
		quinazolin-2-yl)-1H-indol-
		3-yl]-4-oxo-butyric acid
69		4-(5-Chloro-1-{6-furan-2-
		yl-4-[(pyridin-4-
		ylmethyl)-amino]-
		quinazolin-2-yl}-1H-indol-
		3-yl)-4-oxo-butyric acid
70		4-{5-Chloro-1-[6,7-
		dimethoxy-4-(4-methoxy-
		benzylamino)-quinazolin-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
71		4-{5-Bromo-1-[4-(1- carboxy-2-phenyl- ethylamino)-6-furan-2-yl- quinazolin-2-yl]-1H-indol- 3-yl}-4-oxo-butyric acid
72		4-{2-[5-Bromo-3-(3- carboxy-propionyl)-indol- 1-yl]-6-furan-2-yl- quinazolin-4-yl}- piperazine-1-carboxylic acid tert-butyl ester
73		4-[5-Bromo-1-(6-furan-2-
		yl-4-morpholin-4-yl-
		quinazolin-2-yl)-1H-indol-
		3-yl]-4-oxo-butyric acid
74		1-{2-[5-Bromo-3-(3-
		carboxy-propionyl)-indol-
		1-yl]-6-furan-2-yl-
		quinazolin-4-yl}-
		piperidine-4-carboxylic
		acid
75		1-{2-[3-(3-Carboxy-
		propionyl)-5-chloro-indol-
		1-yl]-6-furan-2-yl-
		quinazolin-4-yl}-
		piperidine-4-carboxylic
		acid ethyl ester
76		1-{2-[3-(3-Carboxy-
		propionyl)-5-chloro-indol-
		1-yl]-6-furan-2-yl-
		quinazolin-4-yl}-
		piperidine-4-carboxylic
		acid
77		1-{2-[5-Bromo-3-(3-
		carboxy-propionyl)-indol-
		1-yl]-6-furan-2-yl-
		quinazolin-4-yl}-
		piperidine-4-carboxylic
		acid ethyl ester
78		1-{4-[3-(3-Carboxy- propionyl)-5-chloro-indol- 1-yl]-7-furan-2-yl- quinazolin-2-yl}- piperidine-4-carboxylic acid ethyl ester
79		4-[5-Chloro-1-(6-furan-2-
		yl-4-morpholin-4-yl-
		quinazolin-2-yl)-1H-indol-
		3-yl]-4-oxo-butyric acid
80		1-{2-[3-(3-Carboxy-
		propionyl)-5-chloro-indol-
		1-yl]-6-nitro-quinazolin-
		4-yl}-piperidine-4-
		carboxylic acid ethyl
		ester
81		4-{5-Chloro-1-[6-furan-2-
		yl-4-(4-hydroxy-piperidin-
		1-yl)-quinazolin-2-yl]-1H-
		indol-3-yl}-4-oxo-butyric
		acid
82		1-[2-[3-(3-Carboxy-
		propionyl)-5-chloro-indol-
		1-yl]-6-(2-oxo-pyrrolidin-
		1-yl)-quinazolin-4-yl]-
		piperidine-4-carboxylic
		acid ethyl ester
83		4-{5-Chloro-1-[4-(4-
		hydroxy-piperidin-1-yl)-6-
		trifluoromethyl-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
84		4-{5-Chloro-1-[4-(4-
		hydroxymethyl-piperidin-1-
		yl)-6-trifluoromethyl-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
85		4-{1-[4-(4-tert-Butyl- phenylamino)-6-morpholin- 4-yl-[1,3,5]triazin-2-yl]- 5-chloro-1H-indol-3-yl}-4- oxo-butyric acid
86		2-{2-[5-Bromo-3-(3-
		carboxy-propionyl)-indol
		1-yl]-6-furan-2-yl-
		quinazolin-4-ylamino}-
		butyric acid
87		2-{2-[3-(3-Carboxy-
		propionyl)-5-chloro-indol-
		l-yl]-6-furan-2-yl-
		quinazolin-4-ylamino}-
		butyric acid
88		4-{5-Chloro-1-[6-furan-2-
		yl-4-(2-methanesulfonyl-
		ethylamino)-quinazolin-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
89		4-{1-[4-(Carbamoylmethyl-
		amino)-6-furan-2-yl-
		quinazolin-2-yl]-5-chloro-
		1H-indol-3-yl}-4-oxo-
		butyric acid
90		4-[5-Cyano-1-(4,6-
		diphenyl-pyrimidin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
91		4-{1-[4,6-Bis-(3-methoxy- phenyl)-pyrimidin-2-yl]-5- bromo-1H-indol-3-yl}-4- oxo-butyric acid
92		4-[5-Chloro-1-(4,6-
		diphenyl-pyrimidin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
93		4-[6-Chloro-1-(4,6-
		diphenyl-pyrimidin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
94		4-[5-Bromo-1-(4,6-
		diphenyl-pyrimidin-2-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
95		4-{5-Bromo-1-[4-(3,4- dihydro-2H-quinolin-1-yl)- 6-pyrrolidin-1-yl- [1,3,5]triazin-2-yl]-1H- indol-3-yl}-4-oxo-butyric acid
96		4-{5-Chloro-1-[4-(3-
		methoxy-phenyl)-6-phenyl-
		pyrimidin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
97		4-[5-Chloro-1-(4-phenyl-6-
		phenylamino-pyrimidin-2-
		yl)-1H-indol-3-yl]-4-oxo-
		butyric acid
98		4-{5-Chloro-1-[6-(4-
		chloro-phenyl)-2-phenyl-
		pyrimidin-4-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
99		4-{5-Chloro-1-[5-(4-
		chloro-phenyl)-pyrimidin-
		2-yl]-1H-indol-3-yl}-4-
		oxo-butyric acid
100		4-{5-Chloro-1-[4-
		(dibenzofuran-4-ylamino)-
		benzyl]-1H-indol-3-yl}-4-
		oxo-butyric acid
101		4-{5-Chloro-1-[4-(2-
		methoxy-dibenzofuran-3-
		ylamino)-benzyl]-1H-indol-
		3-yl}-4-oxo-butyric acid
102		4-[5-Chloro-1-(4-
		thianthren-1-yl-benzyl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
103		4-[5-Chloro-1-(4-
		dibenzofuran-4-yl-benzyl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
104		4-[5-Chloro-1-(4-
		dibenzothiophen-4-yl-
		benzyl)-1H-indol-3-yl]-4-
		oxo-butyric acid
105		4-{5-Chloro-1-[4-(4-
		chloro-phenyl)-5-(4-
		methoxy-phenyl)-thiazol-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
106		4-{5-Chloro-1-[4-(4- chloro-phenyl)-5-(4-ethyl- phenyl)-thiazol-2-yl]-1H- indol-3-yl}-4-oxo-butyric acid
107		4-{5-Chloro-1-[4-(4-
		fluoro-phenyl)-5-(4-
		methoxy-phenyl)-thiazol-2-
		yl]-1H-indol-3-yl}-4-oxo-
		butyric acid
108		4-{5-Chloro-1-[2-oxo-2-
		(5,5,8,8-tetramethyl-
		5,6,7,8-tetrahydro-
		naphthalen-2-yl)-ethyl]-
		1H-indol-3-yl}-4-oxo-
		butyric acid
109		4-{5-Chloro-1-[2-(5-
		chloro-3-methyl-
		benzo[b]thiophen-2-yl)-2-
		oxo-ethyl]-1H-indol-3-yl}-
		4-oxo-butyric acid
110		4-[5-Bromo-1-(6-furan-2-
		yl-4-hydroxy-quinazolin-2-
		yl]-1H-indole-3-yl]-4-oxo-
		butyric acid
111		4-(5-Bromo-1-{6-furan-2-
		yl-4-[(furan-2-ylmethyl)-
		amino]-quinazolin-2-yl}-
		1H-indole-3-yl)-4-oxo-
		butyric acid
112		4-{5-Chloro-1-[6-furan-2-
		yl-4-(4-hydroxymethyl-
		piperidin-1-yl)-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
113		4-(5-Chloro-1-{4-[(furan-
		2-ylmethyl)-amino]-6,7-
		dimethoxy-quinazolin-2-
		yl}-1H-indol-3-yl)-4-oxo-
		butyric acid
114		1-{6-Amino-2-[3-(3-
		carboxy-propionyl)-5-
		chloro-indol-1-yl]-
		quinazolin-4-yl}-
		piperidine-4-carboxylic
		acid ethyl ester
115		4-[1-(6-Amino-4-morpholin-
		4-yl-quinazolin-2-yl)-5-
		chloro-1H-indol-3-yl]-4-
		oxo-butyric acid.
116		4-{5-Chloro-1-[4-(4-
		methoxy-benzylamino)-6-
		trifluoromethyl-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
117		4-{5-Chloro-1-[4-(4-
		methoxy-phenylamino)-6-
		trifluoromethyl-
		quinazolin-2-yl]-1H-indol-
		3-yl}-4-oxo-butyric acid
118		2-Chloro-4,6-
		diphenylpyrimidine
119		4-(5-Chloro-1H-indol-3-
		yl)-4-oxo-butyric acid 2-
		trimethylsilanylethyl
		ester
120		4-[5-Chloro-1-(4,6- diphenyl-pyrimidin-2-yl)- 1H-indol-3-yl]-4-oxo- butyric acid 2- trimethylsilanylethyl ester
121		4-[5-Chloro-1-(2,6-
		diphenyl-pyrimidin-4-yl)-
		1H-indol-3-yl]-4-oxo-
		butyric acid
122		4-[5-Chloro-1-(3-cyano-
		4,6-diphenyl-pyridin-2-
		yl)-1H-indol-3-yl]-4-oxo-
		butyric acid
123		2-[4-(4-Butyl-phenyl)-6-
		furan-2-yl-quinazolin-2-
		ylamino]-
		benzenesulfonamide

Example 7a (Compound 123)

Preparation of 2-[4-(4-Butyl-phenyl)-6-furan-2-yl-quinazolin-2-ylamino]-benzenesulfonamide

Step 1: 6-Bromo-1H-benzo[d][1,3]oxazine-2,4-dione

A solution of 2-amino-5-bromo-benzoic acid (15 g, 69 mmol) in acetic anhydride (60 mL) was heated to 130° C. After 16 h, the solution was concentrated, and subsequently azeotroped with toluene (3×100 mL) to remove the remaining acetic anhydride. The resulting brown solid was dried in vacuo to provide 6-bromo-2-methyl-benzo[d][1,3]oxazin-4-one.

Step 2: (2-Amino-5-bromo-phenyl)-(4-butyl-phenyl)-methanone

A solution of 6-bromo-2-methyl-benzo[d][1,3]oxazin-4-one (8.5 g, 35 mmol) in CH₂Cl₂ (100 mL) was cooled to −78° C. and treated with 4-n-butyl phenyl magnesium bromide (71 mL, 35 mmol, 0.5 M in THF). The reaction was slowly warmed to room temperature and stirred overnight and quenched with sat'd ammonium chloride (30 mL). After stirring one hour, the organic layer was extracted with ethyl acetate, dried over sodium sulfate and concentrated to an orange oil. The oil was dissolved in MeOH (50 mL) and treated with 2 N HCl (5 equiv, 177 mmol). After refluxing overnight, the solution was cooled to 0° C. and basified with 1 N NaOH to pH 8. The organic layer was extracted with ethyl acetate, dried over sodium sulfate and concentrated. Purification by flash column chromatography. (5% ethyl acetate in heptane) gave 2-amino-5-bromo-phenyl-4-butyl-phenyl-methanone (6.88 g, 60%) as a yellow solid.

Step 3: 6-Bromo-4-(4-butyl-phenyl)-1H-quinazolin-2-one

A solution of 2-amino-5-bromo-phenyl-4-butyl-phenyl-methanone (6 g, 18 mmol) in acetic acid (50 mL) was treated with urea (3.25 g, 54 mmol) and heated to 130° C. for 4 h. After cooling to room temperature, the solution was concentrated. The resulting solid was dissolved in a minimal amount of CH₂Cl₂ and precipitated with heptane. The resulting solid was filtered, washed with ethyl acetate and dried in vacuo to give 6-bromo-4-butyl-phenyl-1H-quinazolin-2-one (5.50 g, 85%) as a light yellow solid.

Step 4: 6-Bromo-4-(4-butyl-phenyl)-2-chloro-quinazoline

In a glass tube sealed with a teflon cap, a solution of 6-bromo-4-butyl-phenyl-1H-quinazolin-2-one (1 g, 2.8 mmol) in POCl₃ (5 mL) was heated to 130° C. for 2 hours. After cooling to room temperature, the solution was cautiously added to ice water. The resulting precipitate was extracted with CH₂Cl₂, dried over sodium sulfate and concentrated. Purification by flash column chromatography (5% ethyl acetate in heptane) gives 6-bromo-4-(4-butyl-phenyl)-2-chloro-quinazoline (0.59 g, 56%).

Step 5: 2-[6-Bromo-4-(4-butyl-phenyl)-quinazolin-2-ylamino]-benzenesulfonamide

In a glass tube sealed with a teflon cap, a solution of 6-bromo-4-(4-butyl-phenyl)-2-chloro-quinazoline (0.212 g, 0.56 mmol) and 2-aminobenzenesulfanilamide (0.117 g, 0.68 mmol) in diphenyl ether (1 mL) was heated to 175° C. for 48 h. After cooling to room temperature, purification by flash column chromatography (5-30% ethyl acetate/heptane) gives 2-[6-bromo-4-(4-butyl-phenyl)-quinazolin-2-ylamino]-benzenesulfonamide (0.092 g, 32%).

Step 6: 2-[4-(4-Butyl-phenyl)-6-furan-2-yl-quinazolin-2-ylamino]-benzenesulfonamide

A solution of 2-[6-bromo-4-(4-butyl-phenyl)-quinazolin-2-ylamino]-benzenesulfonamide (0.08 g, 0.16 mmol), 2-furanboronic acid (0.023 g, 0.19 mmol), Na₂CO₃ (0.166 g, 1.6 mmol) and Pd(PPh₃)₄ (0.018 g, 0.016 mmol) in ethylene glycol dimethyl ether (3 mL) and water (1 mL) was heated to 80° C. After stirring for 2 h, the solution was diluted with H₂0 (10 mL) and extracted with ethyl acetate. Purification by flash column chromatography (10-40% ethyl acetate/heptane) gives 2-[4-(4-butyl-phenyl)-6-furan-2-yl-quinazolin-2-ylamino]-benzenesulfonamide (0.036 g, 46 R_f=0.20 (5% MeOH in CH₂Cl₂).

Example 8 (Compound 53)

Preparation of 4-[5-Bromo-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid

Step 1: 2-Amino-5-bromo-benzonitrile

Prepared according to the literature procedure by Roche, D. Prasad, K.; Repic, O.; Blacklock, T. J. Tetrahedron Lett. 2000, 41, 2083. R_f 0.46 (40% ethyl acetate in heptane) ¹H NMR (CDCl₃, 300 MHz) δ 7.47 (d, J=2.3 Hz, 1 H), 7.39 (dd, J₁=8.9 Hz, J₂=2.2 Hz, 1 H), 6.62 (d, J=8.9 Hz, 1 H). ESI-LCMS m/z calcd for C₇H₅BrN₂: 196.0; found 197.0 (M+1)⁺.

Step 2: 6-Bromo-1H-quinazoline-2,4-dione

Prepared according to the literature procedure by Mizuno, T.; Okamoto, N, Ito, T.; Miyata, T. Tetrahedron Lett. 2000, 41, 1051 with some modifications.

A mixture of 2-amino-5-bromo-benzonitrile (10 g, 52 mmol) and 1,8-diazobicyclo[5.4.0]-undec-7-ene (DBU) (30 mL, 200 mmol) in dimethylformamide (DMF) (50 mL) was warmed (100° C. bath) with stirring under an atmosphere of carbon dioxide from an attached latex balloon for 48 hours. The solution was removed from the heat, added to cooled (ice bath) 1 N HCl (500 mL) and the solids were collected, washed with H₂O and dried to provide 6-bromo-1H-quinazoline-2,4-dione as a yellow solid (12 g, quantitative): R_f 0.27 (5% methanol in dichloromethane) ¹H NMR (DMSO-d₆, 300 MHz) δ 11.41 (s, 1 H), 11.27 (s, 1 H), 7.91 (d, J=2.3 Hz, 1 H), 7.77 (dd, J₁=8.8 Hz, J₂=2.3 Hz, 1 H), 7.11 (d, J=8.8 Hz, 1 H). ESI-LCMS m/z calcd for C₈H₅BrN₂O₂: 240.0; found 241.0 (M+1)⁺.

Step 3: 6-Furan-2-yl-1H-quinazoline-2,4-dione

A mixture of 6-bromo-1H-quinazoline-2,4-dione (8.0 g, 33 mmol), 2-furanboronic acid (4.5 g, 40 mmol), potassium phosphate (K₃PO₄) (17.5 g, 82 mmol) and tetrakistriphenyphosphine palladium (Pd(PPh₃)₄) (2.0 g, 1.7 mmol) in DMF (80 mL, N₂ degassed) in a Teflon screw cap glass pressure vessel was warmed (100° C. bath) with stirring. After 16 h, the contents were added to H₂O (250 mL), the solids were filtered and washed with H₂O (50 mL). After drying, the solids were stirred in methylene chloride/heptane (4:1, 100 mL), filtered and washed with CH₂Cl₂/heptane ((4:1, 50 mL) to provide 6-furan-2-yl-1H-quinazoline-2,4-dione as a tan solid (7 g, 90%): R_f 0.27 (5% methanol in dichloromethane) ¹H NMR (DMSO-d₆, 300 MHz) δ 8.10 (d, J=2.0 Hz, 1 H), 7.94 (dd, J₁=8.5 Hz, J₂=2.0 Hz, 1 H), 7.73 (d, J=1.6 Hz, 1 H), 7.18 (d, J=8.5 Hz, 1 H), 6.95 (d, J=3.1 Hz, 1 H), 6.58 (dd, J=3.1, 1.6 Hz, 1 H). ESI-LCMS m/z calcd for C₁₂H₈N₂O₃: 228.0; found 229.0 (M+1)⁺.

Step 4: 2,4-Dichloro-6-furan-2-yl-quinazoline

Prepared according to the literature procedure by Fujino, K.; Takami, H.; Atsumi, T.; Ogasa, T.; Mohri, S-I; Kasai, M. Org. Process Res. Dev. 2001, 5, 426 with some modifications. A mixture of 6-furan-2-yl-1H-quinazoline-2,4-dione (1.0 g, 4.4 mmol), phosphorous oxychloride (POCl₃) (2 mL, 21 mmol) and diisopropylethylamine (1.7 mL, 9.7 mmol) in toluene (5 mL) was warmed (85° C. bath) with stirring (3 h). The liquids were removed via distillation, the solids dissolved in toluene/ethyl acetate (EtOAc) (3:1, 20 mL) and the solution was added slowly to cooled (ice bath) 2 M K₂HPO₄ (30 mL) and EtOAc (10 mL). The mixture was filtered, the organic layer separated, dried (Na₂SO₄) and the solvent removed. The solid was dissolved in CH₂Cl₂ and pulled through a 1.5″ plug of silica eluting with EtOAc/heptane (1:1) to provide 2,4-dichloro-6-furan-2-yl-quinazoline as a yellow solid (0.8 g, 66%). R_f 0.63 (n-heptane/EtOAc, 4:1, v/v) ¹H NMR (CDCl₃, 300 MHz) δ 8.44 (d, J=1.9 Hz, 1 H), 8.24 (dd, J=8.9, 1.9 Hz, 1 H), 7.98 (d, J=8.9 Hz, 1 H), 7.59 (d, J=1.6 Hz, 1 H), 6.91 (d, J=3.1 Hz, 1 H), 6.57 (dd, J=3.1, 1.6 Hz, 1 H). ESI-LCMS m/z calcd for C₁₂H₆Cl₂N₂O: 264.0; found 265.0 (M+1)⁺.

Step 5: 2-Chloro-6-furan-2-yl-4-pyridin-2-yl-quinazoline

A mixture of 2,4-dichloro-6-furan-2-yl-quinazoline (1.00 g, 3.80 mmol), 0.5M 2-pyridylzinc bromide (9.0 mL in tetrahydrofuran (THF)) and Pd(PPh₃)₄ (0.25 g, 0.21 mmol) in THF (5 mL) was warmed (90° C. bath) under N₂ with stirring. After 16 h, the mixture was added to 50% NH₄Cl (100 mL) and NaCl (sat.) (10 mL), extracted with CH₂Cl₂ (100 mL and 50 mL) and dried (Na₂SO₄). The crude material was purified by flash chromatography eluting with CH₂Cl₂/EtOAc (32:1, v/v) to provide 2-chloro-6-furan-2-yl-4-pyridin-2-yl-quinazoline as a green-brown solid (0.28 g, 23%): R_f 0.29 (n-heptane/EtOAc, 17:3, v/v) ¹H NMR (CDCl₃, 300 MHz) δ 9.20 (d, J=2.0 Hz, 1 H), 8.87 (br d, J=4.7 Hz, 1 H), 8.27 (d, J=7.8 Hz, 1 H ), 8.21 (dd, J=8.9, 2.0 Hz, 1 H), 8.01 (d, J=8.9 Hz, 1 H ), 7.96 (dt, J=7.8, 1.3 Hz, 1 H), 7.54-7.49 (comp, 2 H), 6.82 (d, J=3.4 Hz, 1 H), 6.52 (dd, J=3.4, 1.9 Hz, 1 H). ESI-LCMS m/z calcd for C₁₇H₁₀ClN₃O: 307.05; found 308.2 (M+1)⁺.

Step 6: 4-[5-Bromo-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid methyl ester

A mixture of 2-chloro-6-furan-2-yl-4-pyridin-2-yl-quinazoline (0.200 g, 0.650 mmol), 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester (0.222 g, 0.710 mmol), K₂CO₃ (0.180 g, 1.30 mmol) and DMAP (cat.) in DMSO (5 mL) under N₂ was warmed (95° C.) with stirring. After 16 h, added H₂O (10 mL) and filtered the solids. The material was pure enough for the next step or the crude material was purified by flash chromatography eluting with CH₂Cl₂/EtOAc (99:1 and 98.5:1.5, v/v) to provide 4-[5-bromo-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid methyl ester as a yellow-green solid (0.36 g, 95%): R_f 0.45 (CH₂Cl₂/EtOAc, 49:1, v/v)

¹H NMR (CDCl₃, 300 MHz) δ 9.17 (s, 1 H), 9.13 (d, J=2.1 Hz, 1 H), 8.95-8.91 (m, 1 H), 8.90 (d, J=8.8 Hz, 1 H), 8.62 (d, J=2.1 Hz, 1 H), 8.29 (d, J=7.7 Hz, 1 H), 8.22 (dd, J=8.6, 2.1 Hz, 1 H), 8.09-8.03 (m, 1 H), 8.08 (d, J=8.6 Hz, 1 H), 7.59 (ddd, J=7.7, 4.7, 1.2 Hz, 1 H), 7.54-7.50 (comp, 2 H), 6.82 (d, J=3.2 Hz, 1 H), 6.53 (dd, J=3.2, 1.8 Hz, 1 H), 3.73 (s, 3 H), 3.37 (t, J=6.7 Hz, 2 H), 2.84 (t, J=6.7 Hz, 2 H). ESI-LCMS m/z calcd for C₃₀H₂₁BrN₄O₄: 580.07; found 581.0 (M+1)⁺.

Step 7: 4-[5-Bromo-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid

A mixture of 4-[5-bromo-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid methyl ester (0.300 g, 0.510 mmol) and NaOH (0.062 g, 1.5 mmol) in DMSO/dioxane/H₂O (14 mL, 4:4:1, v/v) was stirred under N₂ at rt, 3-16 h or 60° C., 4 h. The mixture was acidified (2 N HCl), water was added (20 mL) and the solids were filtered, washed (H₂O) and dried. The material may be recrystallized by dissolving in THF (0.20 mL/mg) and adding hot H₂O or heptane (0.22 mL/mg) to provide 4-[5-bromo-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid as a yellow solid (0.15 g, 52%): R_f 0.28 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.29 (s, 1 H), 9.15 (d, J=2.1 Hz, 1 H), 8.95-891 (m, 1 H), 8.91 (d, J=8.9 Hz, 1 H), 8.50 (d, J=8.4 Hz, 1 H), 8.41-8.37 (comp, 2 H), 8.18 (dt, J=7.6, 1.8 Hz, 1 H), 8.14 (d, J=8.4 Hz, 4 H), 7.84 (d, J=1.7 Hz, 1 H), 7.73 (ddd, J=7.6, 4.7, 1.2 Hz, 1 H), 7.58 (dd, J=8.9, 2.1 Hz, 1 H), 7.17 (d, J=3.2 Hz, 1 H), 6.66 (dd, J=3.2, 1.7 Hz, 1 H), 3.36-3.27 (comp, 2 H), 2.63 (t, J=6.3 Hz, 2 H). ESI-LCMS m/z calcd for C₂₉H₁₉BrN₄O₄: 566.1; found 567.3 (M+1)⁺.

Example 9 (Compound 68)

Preparation of 4-[5-Chloro-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid

Step 1: 4-[5-Chloro-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester

This compound was prepared in a manner analogous to that set forth in example A, except 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester (0.062 mg, 0.176 mmol, 1.1 mole equivalent) was used in step 6 instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester to provide 4-[5-chloro-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester as a brown solid (0.068 g, 68%): R_f 0.39 (heptane/EtOAc, 7:3, v/v) ¹H NMR (CDCl₃, 300 MHz) δ 9.19 (s, 1 H), 9.13 (d, J=2.1 Hz, 1 H), 8.96 (d, J=9.0 Hz, 1 H), 8.95-8.91 (m, 1 H), 8.46 (d, J=1.9 Hz, 1 H), 8.30 (d, J=7.4 Hz, 1 H), 8.22 (dd, J=8.8, 1.9 Hz, 1 H), 8.08 (d, J=8.8 Hz, 1 H), 8.06 (dt, J=7.4, 1.8 Hz, 1 H), 7.58 (ddd, J=7.4, 4.8, 1.2 Hz, 1 H), 7.53 (d, J=1.7 Hz, 1 H), 7.38 (dd, J=9.0, 2.1 Hz, 1 H), 6.82 (d, J=3.2 Hz, 1 H), 6.53 (dd, J=3.2, 1.7 Hz, 1 H), 4.24-4.18 (m, 2 H), 3.60 (t, J=6.9 Hz, 2 H), 2.82 (t, J=6.9 Hz, 2 H), 1.05-0.99 (m, 2 H), 0.05 (s, 9 H). ESI-LCMS m/z calcd for C₃₄H₃₁ClN₄O₄Si: 622.18; found 623.4 (M+1)⁺.

Step 2: 4-[5-Chloro-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid

To a solution of 4-[5-chloro-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester (0.060 g, 0.096 mmol) in THF (1 mL) was added tetra-n-butylammoniumflouride (TBAF) (0.380 mL, 0.38 mmol) at rt with stirring. After 3 h, water (1 mL) and 1 N HCl was added until acidic and the mixture was stirred 1 h. The solids were filtered, washed with water and dried to provide 4-[5-chloro-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indole-3-yl]-4-oxo-butyric acid as a yellow solid (0.027 g, 50%): R_f 0.38 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.35 (s, 1 H), 9.16 (d, J=2.2 Hz, 1 H), 9.00 (d, J=8.9 Hz, 1 H), 8.94 (br d with further small coupling, J=4.8 Hz, 1 H), 8.52 (d, J=8.4 Hz, 1 H), 8.42 (dd, J=8.1, 1.9 Hz, 1 H), 8.27 (d, J=2.1 Hz, 1 H), 8.21 (dt, J=8.1, 1.9 Hz, 1 H), 8.18 (d, J=8.4 Hz, 1 H), 7.85 (d, J=1.6 Hz, 1 H), 7.74 (ddd, J=8.1, 4.8, 1.9 Hz, 1 H), 7.49 (dd, J=8.9, 2.2 Hz, 1 H), 7.19 (d, J=3.6 Hz, 1 H), 6.67 (dd, J=3.6, 1.6 Hz, 1 H), 3.36-3.27 (comp, 2 H), 2.64 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₂₉H₁₉ClN₄O₄: 522.1; found 523.0 (M+1)⁺.

Example 10 (Compound No. 49)

Preparation of 4-{1-[4-(4-Butyl-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example A, except 4-n-butylphenylmagnesium bromide and ZnCl₂ (1 mole equivalent) was used instead of 2-pyridylzinc bromide in step 5 and 4-(1H-indol-3-yl)-4-oxo-butyric acid methyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 to provide 4-{1-[4-(4-Butyl-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl-4-oxo-butyric acid as a yellow solid: R_f 0.20 (Heptane/EtOAC, 3:2, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.07 (br s, 1H), 9.25 (s, 1H), 9.01 (d, J=8 Hz, 1H), 8.42 (dd, J=9, 2 Hz, 1H), 8.30-8.28 (m, 2H), 8.20 (d, J=9 Hz, 1H), 7.92 (d, J=8 Hz, 2H), 7.83 (d, J=2 Hz, 1H), 7.55 (d, J=8 Hz, 2H), 7.48-7.34 (m, 2H), 7.19 ( d, J=3 Hz, 1H), 6.65 (dd, J=3, 2 Hz, 1H), 3.30 (t, J=6 Hz, 2H), 2.77 (t, J=7.5 Hz, 2H), 2.62 (t, J=6 Hz, 2H), 1.75-1.65 (m, 2H), 1.48-1.35 (m, 2H), 0.967 (t, J=7.5 Hz, 3H). ESI-LCMS m/z calcd for C₃₄H₂₉N₃O₄: 543.6; found 544.0 (M+1)⁺.

Example 11 (Compound No. 47)

Preparation of 4-[1-(6-Furan-2-yl-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example A, except phenylmagnesium bromide and ZnCl₂ (1 mole equivalent) was used instead of 2-pyridylzinc bromide in step 5 and 4-(1H-indol-3-yl)-4-oxo-butyric acid methyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 to provide 4-[1-(6-furan-2-yl-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid as a yellow solid: R_f 0.30 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.10 (br s, 1H), 9.26 (s, 1H), 9.01 (d, J=8 Hz, 1H), 8.44 (dd, J=9, 2 Hz, 1H), 8.30 (d, J=8 Hz, 1H), 8.26 (d, J=2 Hz, 1H), 8.22 (d, J=9 Hz, 1H), 8.02-7.98 (m, 2H), 7.82 (d, J=2 Hz, 1H), 7.75-7.72 (m, 3H), 7.48-7.34 (cm, 2H), 7.20 (d, J=3.5 Hz, 1H), 6.65 (dd, J=3.5, 2 Hz, 1H), 3.31 (t, J=6 Hz, 2H), 2.62 (t, J=6 Hz, 2H). ESI-LCMS m/z calcd for C₃₀H₂₁N₃O₄ : 487.5; found 488.0 (M+1)⁺.

Example 12 (Compound No. 48)

Preparation of 4-[5-Bromo-1-(6-furan-2-yl-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example A, except phenylmagnesium bromide and ZnCl₂ (1 mole equivalent) was used instead of 2-pyridylzinc bromide in step 5 to provide 4-[5-Bromo-1-(6-furan-2-yl-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid as a yellow solid: R_f 0.31 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.12 (br s, 1H), 9.23 (s, 1H), 8.89 (d, J=9 Hz, 1H), 8.42-8.37 (m, 2H), 8.21 (d, J=2 Hz, 1H), 8.16 (d, J=9 Hz, 1H), 7.99-7.96 (m, 2H), 7.80 (d, J=2 Hz, 1H), 7.73-7.71 (m, 3H), 7.56 (dd, J=9, 2 Hz, 1H), 7.17 (d, J=3.5 Hz, 1H), 6.64 (dd, J=3.5, 2 Hz, 1H), 3.28 (t, J=6 Hz, 2H), 2.61 (t, J=6 Hz, 2H). ESI-LCMS m/z calcd for C₃₀H₂₀BrN₃O₄: 566.4; found 568.0 (M+1)⁺.

Example 13 (Compound No. 43)

Preparation of 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-phenyl)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example A, except 4-methoxyphenylmagnesium bromide and ZnCl₂ (1 mole equivalent) was used instead of 2-pyridylzinc bromide in step 5 to provide 4-{5-bromo-1-[6-furan-2-yl-4-(4-methoxy-phenyl)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.45 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 12.2 (s, 1 H), 9.25 (s, 1 H), 8.91 (d, J=8.9 Hz, 1 H), 8.41-8.37 (comp, 2 H), 8.30 (s, 1 H), 8.14 (d, J=8.8 Hz, 1 H), 7.99 (d, J=8.8 Hz, 2 H), 7.82 (d, J=1.7 Hz, 1 H), 7.57 (dd, J=8.9, 1.9 Hz, 1 H), 7.27 (d, J=8.8 Hz, 2 H), 7.18 (d, J=3.5 Hz, 1 H), 6.65 (dd, J=3.5, 1.7 Hz, 1 H), 3.93 (s, 3 H), 3.29 (t, J=6.3 Hz, 2 H), 2.62 (t, J=6.3 Hz, 2 H). ESI-LCMS m/z calcd for C₃₁H₂₂BrN₃O₅: 595.1; found 596.0 (M+1)⁺.

Example 14 (Compound No. 44)

Preparation of 4-{5-Bromo-1-[4-(4-cyano-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example A, except 4-cyanophenylzinc bromide was used instead of 2-pyridylzinc bromide in step 5 to provide 4-{5-Bromo-1-[4-(4-cyano-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.30 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (CDCl₃, 300 MHz) δ 9.09 (s, 1 H), 8.82 (d, J=9.1 Hz, 1 H), 8.57 (d, J=2.0 Hz, 1 H), 8.24-8.19 (comp, 2 H), 8.10 (d, J=8.8 Hz, 1 H), 7.99 (d, J=2.3 Hz, 4 H), 7.53 (d, J=1.8 Hz, 1 H), 7.48 (dd, J=9.1, 2.0 Hz, 1 H), 6.81 (d, J=3.2 Hz, 2 H), 6.54 (dd, J=3.2, 1.8 Hz, 1 H), 3.41 (t, J=6.6 Hz, 2 H), 2.87 (t, J=6.6 Hz, 2 H). ESI-LCMS m/z calcd for C₃₁H₁₉BrN₄O₄: 590.1; found 591.0 (M+1)⁺.

Example 15 (Compound No. 45)

Preparation of 4-{5-Bromo-1-[4-(4-fluoro-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example A, except 4-fluorophenylzinc bromide was used instead of 2-pyridylzinc bromide in step 5 to provide 4-{5-bromo-1-[4-(4-fluoro-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.32 (CH₂Cl₂/MeOH, 19:1, v/v). ESI-LCMS m/z calcd for C₃₀H₁₉BrFN₃O₄: 583.0; found 584.0 (M+1)⁺.

Example 16 (Compound No. 64)

Preparation of 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-phenylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid

Step 1: 2-Amino-5-bromo-benzonitrile

Prepared according to the literature procedure by Roche, D. Prasad, K.; Repic, O.; Blacklock, T. J. Tetrahedron Lett. 2000, 41, 2083.

R_f 0.46 (n-heptane/EtOAc, 3:2, v/v) ¹H NMR (CDCl₃, 300 MHz) δ 7.47 (d, J=2.3 Hz, 1 H), 7.39 (dd, J=8.9, 2.2 Hz, 1 H), 6.62 (d, J=8.9 Hz, 1 H). ESI-LCMS m/z calcd for C₇H₅BrN₂: 196.0 found 197.0 (M+1)⁺.

Step 2: 6-Bromo-1H-quinazoline-2,4-dione

Prepared according to the literature procedure by Mizuno, T.; Okamoto, N, Ito, T.; Miyata, T. Tetrahedron Lett. 2000, 41, 1051 with some modifications.

A mixture of 2-amino-5-bromo-benzonitrile (10 g, 52 mmol) and 1,8-diazobicyclo[5.4.0]-undec-7-ene (DBU) (30 mL, 200 mmol) in dimethylformamide (DMF) (50 mL) was warmed (100° C.) with stirring under an atmosphere of carbon dioxide from an attached latex balloon for 48 hours. The solution was removed from the heat, added to cooled (ice bath) 1N HCl (500 mL) and the solids were collected, washed with H₂O and dried to provide 6-bromo-1H-quinazoline-2,4-dione as a yellow solid (12 g, quantitative): R_f 0.27 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 11.41 (s, 1 H), 11.27 (s, 1 H), 7.91 (d, J=2.3 Hz, 1 H), 7.77 (dd, J=8.8, 2.3 Hz, 1 H), 7.11 (d, J=8.8 Hz, 1 H). ESI-LCMS m/z calcd for C₈H₅BrN₂O₂: 240.0; found 241.0 (M+1)⁺.

Step 3: 6-Furan-2-yl-1H-quinazoline-2,4-dione

A mixture of 6-bromo-1H-quinazoline-2,4-dione (8.0 g, 33 mmol), 2-furanboronic acid (4.5 g, 40 mmol), potassium phosphate (K₃PO₄) (17.5 g, 82 mmol) and tetrakistriphenyphosphine palladium (Pd(PPh₃)₄) (2.0 g, 1.7 mmol) in DMF (80 mL, N₂ degassed) in a Teflon screw cap glass pressure vessel was warmed (100° C. bath) with stirring. After 16 h, the contents were added to H₂O (250 mL), the solids were filtered and washed with H₂O (50 mL). After drying, the solids were stirred in methylene chloride/heptane (4:1, 100 mL), filtered and washed with CH₂Cl₂/heptane ((4:1, 50 mL) to provide 6-furan-2-yl-1H-quinazoline-2,4-dione as a tan solid (7 g, 90%): R_f 0.27 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-₆, 300 MHz) δ 8.10 (d, J=2.0 Hz, 1 H), 7.94 (dd, J=8.5, 2.0 Hz, 1 H), 7.73 (d, J=1.6 Hz, 1 H), 7.18 (d, J=8.5 Hz, 1 H), 6.95 (d, J=3.1 Hz, 1 H), 6.58 (dd, J=3.1, 1.6 Hz, 1 H). ESI-LCMS m/z calcd for C₁₂H₈N₂O₃: 228.0; found 229.0 (M+1)⁺.

Step 4: 2,4-Dichloro-6-furan-2-yl-quinazoline

Prepared according to the literature procedure by Fujino, K.; Takami, H.; Atsumi, T.; Ogasa, T.; Mohri, S-I; Kasai, M. Org. Process Res. Dev. 2001, 5, 426 with some modifications. A mixture of 6-furan-2-yl-1H-quinazoline-2,4-dione (1.0 g, 4.4 mmol), phosphorous oxychloride (POCl₃) (2 mL, 21 mmol) and diisopropylethylamine (1.7 mL, 9.7 mmol) in toluene (5 mL) was warmed (85° C. bath) with stirring (3 h). The liquids were removed via distillation, the solids dissolved in toluene/ethyl acetate (EtOAc) (3:1, 20 mL) and the solution was added slowly to cooled (ice bath) 2M K₂HPO₄ (30 mL) and EtOAc (10 mL). The mixture was filtered, the organic layer separated, dried (Na₂SO₄) and the solvent removed. The solid was dissolved in CH₂Cl₂ and pulled through a 1.5″ plug of silica eluting with EtOAc/heptane (1:1) to provide 2,4-dichloro-6-furan-2-yl-quinazoline as a yellow solid (0.8 g, 66%). R_f 0.63 (n-heptane/EtOAc, 4:1, v/v) ¹H NMR (CDCl₃, 300 MHz) δ 8.44 (d, J=1.9 Hz, 1 H), 8.24 (dd, J=8.9, 1.9 Hz, 1 H), 7.98 (d, J=8.9 Hz, 1 H), 7.59 (d, J=1.6 Hz, 1 H), 6.91 (d, J=3.1 Hz, 1 H), 6.57 (dd, J=3.1, 1.6 Hz, 1 H). ESI-LCMS m/z calcd for C₁₂H₆Cl₂N₂O: 264.0; found 265.0 (M+1)⁺.

Step 5: 2-Chloro-6-furan-2-yl-quinazolin-4-yl-(4-methoxy-phenyl)-amine

To a solution of 2,4-dichloro-6-furan-2-yl-quinazoline (0.100 g, 0.38 mmol) and p-anisidine (0.043 g, 0.035 mmol) in THF (1 mL) was added with stirring under an atmosphere of N₂ at rt triethyl amine (52 uL, 0.38 mmol). After 24 h, EtOAc (5 mL) was added and the mixture was washed with NH₄Cl (50%), sat. NaHCO₃ and the organic dried (Na₂SO₄). The crude material was purified by flash chromatography eluting with heptane/EtOAc (7:3 and 3:2, v/v) to provide 2-chloro-6-furan-2-yl-quinazolin-4-yl-(4-methoxy-phenyl)-amine as a yellow solid (0.12 g, 98%). R_f 0.07 (n-heptane/EtOAc, 3:17, v/v) ¹H NMR (CDCl₃, 300 MHz) δ 8.06 (d, J=1.8 Hz, 1 H), 8.01 (dd, J=8.8, 1.8 Hz, 1 H), 7.80 (d, J=8.8 Hz, 1 H), 7.64 (d, J=9.1 Hz, 2 H), 7.57 (brs, 1 H), 7.52 (dd, J=1.8, 0.7 Hz, 1 H), 6.96 (d, J=9.1 Hz, 2 H), 6.79 (dd, J=3.5, 0.7 Hz, 1 H), 6.54 (dd, J=3.5, 1.8 Hz, 1 H), 3.84 (s, 3 H). ESI-LCMS m/z calcd for C₁₉H₁₄ClN₃O₂: 351.1; found 352.0 (M+1).

Step 6: 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-phenylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid methyl ester

A mixture of 2-chloro-6-furan-2-yl-quinazolin-4-yl-(4-methoxy-phenyl)-amine (0.300 g, 0.850 mmol), 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester (0.290 g, 0.940 mmol), K₂CO₃ (0.300 g, 2.20 mmol) and DMAP (cat.) in DMSO (2 mL) under N₂ was warmed (95° C.) with stirring. After 16 h, added H₂O (10 mL) and filtered the solids. The material was pure enough for the next step or the crude material was extracted into EtOAc and purified by flash chromatography eluting with heptane/EtOAc (19:1-3:2, v/v) or crude material was dissolved in a minimum of THF, MeOH or CH₂Cl₂ and precipitated with heptane to provide 4-{5-bromo-1-[6-furan-2-yl-4-(4-methoxy-phenylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid methyl ester as a tan solid (0.200 g, 37%): R_f 0.31 (n-heptane/EtOAc, 3:2, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 10.39 (s, 1 H), 9.01 (s, 1 H), 8.83 (d, J=2.9 Hz, 1H), 8.62 (dd, J=9.0, 2.9 Hz, 1 H), 8.33 (d, J=2.0 Hz, 1 H), 8.19 (dd, J=8.6, 2.0 Hz, 1 H), 7.87-7.83 (comp, 2 H), 7.69-7.64 (comp, 2 H), 7.33 (dt, J=9.0, 2.9 Hz, 1 H), 7.12-7.08 (comp, 3 H), 6.69 (dd, J=3.4, 1.8 Hz, 1 H), 3.84 (s, 3 H), 3.61 (s, 3 H), 3.26 (t, J=6.5 Hz, 2 H), 2.69 (t, J=6.5 Hz, 2 H). ESI-LCMS m/z calcd for C₃₂H₂₅BrN₄O₅: 624.10; found 625.0 (M+1)⁺.

Step 7: 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-phenylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid

A mixture of 4-{5-bromo-1-[6-furan-2-yl-4-(4-methoxy-phenylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid methyl ester (0.100 g, 0.160 mmol) and NaOH (0.020 g, 0.50 mmol) in DMSO/dioxane/H₂O (5 mL, 4:4:1, v/v) was stirred under N₂ at rt, 3-16 h or 60° C., 4 h. The mixture was acidified (2 N HCl) water was added (20 mL) and the solids were filtered, washed (H₂O) and dried. The material may be recrystallized by dissolving in THF (0.20 mL/mg) and adding hot H₂O or heptane (0.22 mL/mg) to provide 4-{5-bromo-1-[6-furan-2-yl-4-(4-methoxy-phenylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid as a yellow solid (0.100 g, quant.): R_f 0.26 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 10.4 (s, 1 H), 9.01 (s, 1 H) 8.85 (s, 1 H), 8.62 (d, J=8.9 Hz, 1 H), 8.34 (d, J=2.1 Hz, 1 H), 8.19 (d, J=9.1 Hz, 1 H), 7.87-7.84 (comp, 2 H), 7.67 (d, J=8.8 Hz, 2 H), 7.33 (d, J=8.9 Hz, 1 H), 7.12-7.08 (comp, 3 H), 6.69 (dd, J=3.4, 1.9 Hz, 1 H), 3.83 (s, 3 H), 3.20 (t, J=6.4 Hz, 2 H), 2.62 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₃₁H₂₃BrN₄O₅: 610.09; found 611.0 (M+1)⁺.

Example 17 (Compound No. 65)

Preparation of 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-benzylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except used 4-methoxybenzyl amine instead of p-anisidine in step 5 to provide 4-{5-bromo-1-[6-furan-2-yl-4-(4-methoxy-benzylamino)-quinazolin-2-yl]-1H-indole-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.26 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.60 (br, 1 H), 9.07 (s, 1 H), 8.79 (d, J=9.1 Hz, 1 H), 8.70 (s, 1 H), 8.36 (d, J=2.1 Hz, 1 H), 8.14 (dd, J=8.7, 2.0 Hz, 1 H), 7.84 (s, 1 H), 7.81 (d, J=8.7 Hz, 1 H), 7.49-7.42 (comp, 3 H), 7.07 (d, J=3.2 Hz, 1 H), 6.92 (d, J=8.6 Hz, 2 H), 6.67 (dd, J=3.2, 1.7 Hz, 1 H), 4.82 (br, 2 H), 3.69 (s, 3 H), 3.28 (t, J=6.4 Hz, 2 H), 2.64 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₃₂H₂₅BrN₄O₅: 624.1; found 625.0 (M+1)⁺.

Example 18 (Compound No. 110)

Preparation of 4-[5-Bromo-1-(6-furan-2-yl-4-hydroxy-quinazolin-2-yl]-1H-indole-3-yl]-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except used ethanol instead of p-anisidine in step 5 to provide 4-[5-bromo-1-(6-furan-2-yl-4-hydroxy-quinazolin-2-yl]-1H-indole-3-yl]-4-oxo-butyric acid as a yellow solid: R_f 0.30 (CH₂Cl₂/MeOH, 9:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 12.19 (br, 1 H), 9.16 (s, 1 H), 8.65 (d, J=8.7 Hz, 1 H), 8.37-8.36 (comp, 2 H), 8.18 (dd, J=8.5, 2.4 Hz, 1 H), 7.82-7.79 (comp, 2 H), 7.58 (dd, J=8.7, 2.1 Hz, 1 H), 7.16 (d, J=3.4 Hz, 1 H), 6.65 (dd, J=3.4, 1.9 Hz, 1 H), 3.22 (t, J=6.4 Hz, 2 H), 2.64 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₂₄H₁₆BrN₃O₅: 505.0; found 506.0 (M+1)⁺.

Example 19 (Compound No. 111)

Preparation of 4-(5-Bromo-1-{6-furan-2-yl-4-[(furan-2-ylmethyl)-amino]-quinazolin-2-yl}-1H-indole-3-yl)-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except used furfurylamine instead of p-anisidine in step 5 to provide 4-(5-bromo-1-{6-furan-2-yl-4-[(furan-2-ylmethyl)-amino]-quinazolin-2-yl}-1H-indole-3-yl)-4-oxo-butyric acid as a brown amorphous solid: R_f 0.64 (CH₂Cl₂/MeOH, 12:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.45 (br, 1 H), 9.19 (s, 1 H), 8.89 (d, J=9.1 Hz, 1 H), 8.69 (br s, 1 H), 8.41 (d, J=1.9 Hz, 1 H), 8.17 (dd, J=8.8, 1.9 Hz, 1 H), 7.86-7.83 (comp, 2 H), 7.66 (s, 1 H), 7.54 (dd, J=9.1, 2.1 Hz, 1 H), 7.08 (d, J=3.2 Hz, 1 H), 6.69 (dd, J=3.2, 1.8 Hz, 1 H), 6.51-6.40 (comp, 2 H), 4.94 (d, J=5.3 Hz, 1 H), 3.32 (t, J=6.2 Hz, 2 H), 2.66 (t, J=6.2 Hz, 2 H). ESI-LCMS m/z calcd for C₂₉H₂₁BrN₄O₅: 584.07; found 585.0 (M+1)⁺.

Example 20 (Compound No. 86)

Preparation of 2-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-ylamino}-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except used 2-amino-n-butyric acid methyl ester instead of p-anisidine in step 5 to provide 2-{2-[5-bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-ylamino}-butyric acid as a brown solid: R_f 0.38 (CH₂Cl₂/MeOH, 17:3, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.15 (s, 1 H), 9.02 (d, J=6.6 Hz, 1 H), 8.96 (d, J=9.0 Hz, 1 H), 8.80 (s, 1 H), 8.39 (d, J=1.9 Hz, 1 H), 8.18 (dd, J=8.8, 1.9 Hz, 1 H), 7.86 (d, J=8.8 Hz, 1 H), 7.86 (d, J=1.7 Hz, 1 H), 7.54 (dd, J=9.0, 2.2 Hz, 1 H), 7.10 (d, J=3.3 Hz, 1 H), 6.68 (dd, J=3.3, 1.7 Hz, 1 H), 4.53 (q, J=6.6 Hz, 1 H), 3.26 (t, J=6.1 Hz, 2 H), 2.63 (t, J=6.1 Hz, 2 H), 2.12-2.02 (m, 2 H), 1.13 (t, J=7.3 Hz, 3 H) ESI-LCMS m/z calcd for C₂₈H₂₃BrN₄O₆: 590.08; found 591.0 (M+1)⁺.

Example 21 (Compound No. 87)

Preparation of 2-{2-[5-Chloro-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-ylamino}-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 2-amino-n-butyric acid methyl ester was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid allyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 to provide 2-{2-[5-chloro-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-ylamino}-butyric acid as a tan solid: R_f 0.38 (CH₂Cl₂/MeOH, 17:3, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.18 (s, 1 H), 9.02 (d, J=8.9 Hz, 1 H), 9.04-9.02 (m, 1 H), 8.81 (s, 1 H), 8.24 (d, J=2.0 Hz, 1 H), 8.18 (dd, J=8.6, 2.0 Hz, 1 H), 7.88-7.85 (comp, 2 H), 7.42 (dd, J=8.9, 2.2 Hz, 1 H), 7.10 (d, J=2.2 Hz, 1 H), 6.69 (dd, J=3.4, 2.2 Hz, 1 H), 4.53 (q, J=7.2 Hz, 1 H), 3.26 (t, J=6.3 Hz, 2 H), 2.63 (t, J=6.3 Hz, 2 H), 2.07 (p, J=7.2 Hz, 2 H), 1.13 (t, J=7.2 Hz, 3 H). ESI-LCMS m/z calcd for C₂₈H₂₃ClN₄O₆: 546.13; found 547.0 (M+1)⁺.

Example 22 (Compound No. 74)

Preparation of 1-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid

This compound Was prepared in a manner analogous to that set forth in example C, except piperidine-4-carboxylic acid ethyl ester was used instead of p-anisidine in step 5 to provide 1-{2-[5-bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid as a tan solid R_f 0.25 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.26 (br s, 2H), 9.12 (s, 1H), 8.85 (d J=9 Hz, 1H), 8.37 (d, J=2 Hz, 1H), 8.16 (dd, J=9, 2 Hz, 1H), 8.13 (d, J=2 Hz, 1H), 7.88 (d, J=9 Hz, 1H), 7.84 (d, J=2 Hz, 1H), 7.54 (dd, J=9, 2 Hz, 1H), 7.12 (d, J=3 Hz, 1H), 6.65 (dd, J=3, 2 Hz, 1H), 4.43-4.38 (m, 2H), 3.53-3.45 (m, 2H), 3.28 (t, J=6 Hz, 2H), 2.73-2.69 (m, 1H), 2.62 (t, J=6 Hz, 2H), 2.13-2.09 (m, 2H), 1.94-1.83 (m, 2H). ESI-LCMS m/z calcd for C₃₀H₂₅BrN₄O₆: 617.5 found 619.0 (M+1)⁺.

Example 23 (Compound No. 76)

Preparation of 1-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid

This compound was prepared in a manner analogous to that set forth in example C, except piperidine-4-carboxylic acid ethyl ester was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 to provide 1-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid as a white solid: R_f 0.33 (CH₂Cl₂/MeOH, 33:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.25 (br s, 2H), 9.17 (s, 1H), 8.94 (d, J=9 Hz, 1H), 8.24 (d, J=2 Hz, 1H), 8.18 (dd, J=9, 2 Hz, 1H), 8.15 (d, J=2 Hz, 1H), 7.91 (d, J=9 Hz, 1H), 7.84 (d, J=2 Hz, 1H), 7.45 (dd, J=9, 2 Hz, 1H), 7.14 (d, J=3 Hz, 1H), 6.66 (dd, J=3, 2 Hz, 1H), 4.44-4.39 (m, 2H), 3.54-3.47 (m, 2H), 3.29 (t, J=6 Hz, 2H), 2.74-2.70 (m, 1H), 2.62 (t, J=6 Hz, 2H), 2.13-2.09 (m, 2H), 1.95-1.87 (m, 2H). ESI-LCMS m/z calcd for C₃₀H₂₅ClN₄O₆: 573.0 found 573.3 (M+1)⁺.

Example 24 (Compound No. 75)

Preparation of 1-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester

This compound Was prepared in a manner analogous to that set forth in example C, except piperidine-4-carboxylic acid ethyl ester was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of the trimethylsilanyl-ethyl ester with tetra-n-butylammoniumflouride (TBAF) and 1 N HCl to provide 1-{2-[3-(3-carboxy-propionyl)-5-chloro-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester: R_f 0.30 (CH₂Cl₂/MeOH, 33:1, v/v). ¹H NMR (CDCl₃, 300 MHz) δ 9.00 (s, 1H) 8.80 (d, J=9 Hz, 1H), 8.38 (d, J=2 Hz, 1H), 8.11 (d, J=2 Hz, 1H), 7.98 (dd, J=9, 2 Hz, 1H), 7.84 (d, J=9 Hz, 1H), 7.52 (d, J=2 Hz, 1H), 7.31 (dd, J=9, 2 Hz, 1H), 6.74 (d, J=3 Hz, 1H), 6.53 (dd, J=3, 2 Hz, 1H), 4.41-4.36 (m, 2H), 4.21 (q, J=7 Hz, 2H), 3.46-3.39 (m, 2H), 3.34 (t, J=6 Hz, 2H), 2.84 (t, J=6 Hz, 2H), 2.78-2.71 (m, 1H), 2.23-2.04 (m, 4H), 1.31 (t, J=7 Hz, 3H). ESI-LCMS m/z calcd for C₃₂H₂₉ClN₄O₆ 601.0; found 601.3 (M+1)⁺.

Example 25 (Compound No. 77)

Preparation of 1-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester

This compound was prepared in a manner analogous to that set forth in example C, except piperidine-4-carboxylic acid ethyl ester was used instead of p-anisidine in step 5 and 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 1-{2-[5-bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester as a white solid: R_f 0.34 (CH₂Cl₂/MeOH, 33:1, v/v). ¹H NMR (CDCl₃, 300 MHz) δ 9.02 (s, 1H), 8.78 ( d, J=9 Hz, 1H), 8.57 (d, J=2 Hz, 1H), 8.13 (d, J=2 Hz, 1H) 7.99 (dd, J=9, 2 Hz, 1H), 7.86 (d, J=9 Hz, 1H), 7.52 (d , J=2 Hz, 1H), 7.46 (dd, J=9, 2 Hz, 1H), 6.74 (d, J=3 Hz, 1H), 6.53 (dd, J=3, 2 Hz, 1H), 4.42-4.38 (m, 2H), 4.21 (q, J=7 Hz, 2H), 3.48-3.40 (m, 2H), 3.35 (t, J=6 HZ, 2H), 2.87 (t, J=6 Hz, 2H), 2.78-2.71 (m, 1H), 2.24-2.04 (m, 4H), 1.31 (t, J=7 Hz, 3H).

Example 26 (Compound No. 79)

Preparation of 4-[5-Chloro-1-(6-furan-2-yl-4-morpholin-4-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except morpholine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-[5-chloro-1-(6-furan-2-yl-4-morpholin-4-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid as a white solid: R_f 0.23 (CH₂Cl₂/MeOH, 33:1, v/v). 1H NMR (DMSO-d₆, 300 MHz) δ 12.12 ( br s, 1H), 9.12 (s, 1H), 8.88 (d, J=9 Hz, 1H), 8.21 (d, J=2 Hz, 1H), 8.19-8.16 (m, 2H), 7.91 (d, J=9 Hz, 1H), 7.83 (d, J=2 Hz, 1H), 7.41 (dd, J=9, 2 Hz, 1H), 7.14 (d, J=3 Hz, 1H), 6.65 (dd, J=3, 2 Hz, 1H), 3.97-3.96 (m, 4H), 3.88-3.87 (m, 4H), 3.27 (t, J=6 Hz, 2H), 2.62 (t, J=6 Hz, 2H). ESI-LCMS m/z calcd for C₂₈H₂₃ClN₄O₅: 530.9; found 531.3 (M+1)⁺.

Example 27 (Compound No. 81)

Preparation of 4-{5-Chloro-1-[6-furan-2-yl-4-(4-hydroxy-piperidin-1-yl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 4-hydroxypiperidine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[6-furan-2-yl-4-(4-hydroxy-piperidin-1-yl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.18 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.10 (br s, 1H), 9.15 (s, 1H), 8.92 (d, J=9 Hz, 1H), 8.23 (d, J=2 Hz, 1H), 8.18-8.15 (m, 2H), 7.89 (d, J=9 Hz, 1H), 7.82 (d, J=2 Hz, 1H), 7.43 (dd, J=9, 2 Hz, 1H), 7.12 (d, J=3 Hz, 1H), 6.65 (dd, J=3, 2 Hz, 1H), 4.89 (br s, 1H) 4.26-4.22 (m, 2H), 3.90 (m, 1H), 3.68-3.58 (m, 2H), 3.28 (t, J=6 Hz, 2H), 2.62 (t, J=6 Hz, 2H), 2.02 (m, 2H), 1.75-1.68 (m, 2H).

Example 28 (Compound No. 112)

Preparation of 4-{5-Chloro-1-[6-furan-2-yl-4-(4-hydroxymethyl-piperidin-1-yl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 4-hydroxymethylpiperidine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[6-furan-2-yl-4-(4-hydroxymethyl-piperidin-1-yl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a yellow solid:; R_f 0.20 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.10 (br s, 1H), 9.15 (s, 1H), 8.92 (d, J=9 Hz, 1H) 8.22 (d, J=2 Hz, 1H), 8.18-8.15 (m, 2H), 7.89 (d, J=9 Hz, 1H), 7.83 (d, J=2 Hz, 1H), 7.43 (dd, J=9, 2 Hz, 1H), 7.12 (d, J=3 Hz, 1H), 6.65 (dd, J=3, 2 Hz, 1H), 4.61 (br s, 1H), 4.54-4.50 (m, 2H), 3.36-3.33 (m, 4H), 3.28 (t, J=6 Hz, 2H), 2.62 (t, J=6 Hz, 2H), 1.95-1.83 (m, 3H), 1.55-1.50 (m, 2H).

Example 29 (Compound No. 67)

Preparation of 4-{5-Chloro-1-[4-(4-fluoro-benzylamino)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 4-fluoro-benzylamine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[4-(4-fluoro-benzylamino)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a light yellow solid: R_f 0.40 (CH₂Cl₂/MeOH, 33:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 12.15 (br s, 1H), 9.55 (t, J=5 Hz, 1H), 9.01 (s, 1H), 8.81 (d, J=9 Hz, 1H), 8.67 (d, J=2 Hz, 1H), 8.20 (d, J=2 Hz, 1H), 8.15 (dd, J=9, 2 Hz, 1H), 7.84 (d, J=2 Hz, 1H) 7.82 (d, J=9 Hz, 1H), 7.58-7.53 (m, 2H), 7.34 (dd, J=9, 2 Hz, 1H), 7.22-7.16 (m, 2H), 7.06 (d, J=3 Hz, 1H), 6.67 (dd, J=3, 2 Hz, 1H), 4.89 (d, J=5 Hz, 2H), 3.26 (t, J=6 Hz, 2H), 2.64 (t, J=6 Hz, 2H). ESI-LCMS m/z calcd for C₃₁H₂₂ClFN₄O₄: 568.9; found 569.3 (M+1)⁺.

Example 30 (Compound No. 69)

Preparation of 4-(5-Chloro-1-{6-furan-2-yl-4-[(pyridin-4-ylmethyl)-amino]-quinazolin-2-yl}-1H-indol-3-yl)-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 4-(aminomethyl)pyridine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-(5-chloro-1-{6-furan-2-yl-4-[(pyridin-4-ylmethyl)-amino]-quinazolin-2-yl}-1H-indol-3-yl)-4-oxo-butyric acid as a tan solid: R_f 0.10 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 9.89 (t, J=5 Hz, 1H), 8.89 (s, 1H), 8.80-8.78 (m, 3H), 8.72 (d, J=9 Hz, 1H), 8.22-8.17 (m, 2H), 8.09 (d, J=6 Hz, 2H), 7.88-7.85 (m, 2H), 7.34 (dd, J=9, 2 Hz, 1H), 7.13 (d, J=3 Hz, 1H), 6.69 (dd, J=3, 2 Hz, 1H), 5.14 (d, J=5 Hz, 2H), 3.21 (t, J=6 Hz, 2H), 2.63 (t, J=6 Hz, 2H).

Example 31 (Compound No. 89)

Preparation of 4-{1-[4-(Carbamoylmethyl-amino)-6-furan-2-yl-quinazolin-2-yl]-5-chloro-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except glycinamide was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl )-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{1-[4-(carbamoylmethyl-amino)-6-furan-2-yl-quinazolin-2-yl]-5-chloro-1H-indol-3-yl}-4-oxo-butyric acid as a tan solid R_f 0.27 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 9.32 (br s, 1H), 9.21 (s, 1H), 8.97 (d, J=9 Hz, 1H), 8.64 (d, J=2 Hz, 1H), 8.22 (d, J=2 Hz, 1H), 8.15 (dd, J=9, 2 Hz, 1H), 7.85-7.82 (m, 2H), 7.41 (dd, J=9, 2 Hz, 1H), 7.25 (m, 2H), 7.05 (d, J=3 Hz, 1H), 6.66 (dd, J=3, 2 Hz, 1H), 4.18 (d, J=5 Hz, 2H), 3.25 (t, J=6 Hz, 2H), 2.60 (t, J=6 Hz, 2H). ESI-LCMS m/z calcd for C₂₆H₂₀ClN₅₆O₅: 517.9.; found 516.5 (M−1)⁻.

Example 32 (Compound No. 88)

Preparation of 4-{5-Chloro-1-[6-furan-2-yl-4-(2-methanesulfonyl-ethylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 2-aminoethylmethyl sulfone was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[6-furan-2-yl-4-(2-methanesulfonyl-ethylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.22 (CH₂Cl₂/MeOH, 19:1, v/v). ¹H NMR (DMSO-d₆, 300 MHz) δ 9.25 (m, 2H), 8.98 (d, J=9 Hz, 1H), 8.53 (s, 1H), 8.21 (d, J=2 Hz, 1H), 8.11 (d, J=9 Hz, 1H), 7.82-7.79 (m, 2H), 7.39 (dd, J=9, 2 Hz, 1H), 7.04 (d, J=3, 2 Hz, 1H), 6.66 (dd, J=3, 2 Hz, 1H), 4.11 (m, 2H), 3.63 (m, 2H), 3.24 (t, J=6 Hz, 2H), 3.12 (s, 3H), 2.56 (t, J=6 Hz, 2H). ESI-LCMS m/z calcd for C₂₇H₂₃ClN₄O₆S: 567.0; found 567.3 (M+1)⁺.

Example 33 (Compound No. 113)

Preparation of 4-(5-Chloro-1-{4-[(furan-2-ylmethyl)-amino]-6,7-dimethoxy-quinazolin-2-yl}-1H-indol-3-yl)-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except furfurylamine and 2,4-dichloro-6,7-dimethoxyquinazoline was used instead of p-anisidine and 2,4-dichloro-6-furan-2-yl-quinazoline in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-(5-chloro-1-{4-[(furan-2-ylmethyl)-amino]-6,7-dimethoxy-quinazolin-2-yl}-1H-indol-3-yl)-4-oxo-butyric acid as a yellow solid: R_f 0.18 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.18 (s, 1 H), 8.94-8.91 (m, 1 H), 8.93 (d, J=8.9 Hz, 1 H), 8.23 (d, J=2.2 Hz, 1 H), 7.74 (s, 1 H), 7.63 (s with further small coupling, 1 H), 7.39 (dd, J=8.9, 2.2 Hz, 1 H), 7.26 (s, 1 H), 6.45-6.41 (comp, 2 H), 4.88 (d, J=3.8 Hz, 1 H), 3.95 (s, 3 H), 3.90 (s, 3 H), 3.28 (t, J=6.4 Hz, 2 H), 2.64 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₂₇H₂₃ClN₄O₆: 534.13; found 533.0 (M−1)⁻.

Example 34 (Compound No. 70)

Preparation of 4-{5-Chloro-1-[6,7-dimethoxy-4-(4-methoxy-benzylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 4-methoxybenzyl amine and 2,4-dichloro-6,7-dimethoxyquinazoline was used instead of p-anisidine and 2,4-dichloro-6-furan-2-yl-quinazoline in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[6,7-dimethoxy-4-(4-methoxy-benzylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.18 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.08 (s, 1 H), 9.0 (br s, 1 H), 8.84 (d, J=8.8 Hz, 1 H), 8.21 (d, J=2.3 Hz, 1 H), 7.75 (s, 1 H), 7.41 (d, J=8.8 Hz, 2 H), 7.33 (dd, J=8.8, 2.3 Hz, 1 H), 7.25 (s, 1 H), 6.92 (d, J=8.8 Hz, 2 H), 4.80 (br d, J=4.7 Hz, 1 H), 3.95 (s, 3 H), 3.91 (s, 3 H), 3.69 (s, 3 H), 3.26 (t, J=6.5 Hz, 2 H), 2.64 (t, J=6.5 Hz, 2 H). ESI-LCMS m/z calcd for C₃₀H₂₇ClN₄O₆: 574.16; found 573.0 (M−1)⁻.

Example 35 (Compound No. 80)

Preparation of 1-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-nitro-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester

This compound was prepared in a manner analogous to that set forth in example C, except 2-amino-5-nitro-benzonitrile was used instead of 2-amino-5-bromo-benzonitrile in step 1, piperidine-4-carboxylic acid ethyl ester was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 1-{2-[3-(3-carboxy-propionyl)-5-chloro-indol-1-yl]-6-nitro-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester as a yellow solid R_f 0.28 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.15 (s, 1 H), 8.88 (d, J=8.8 Hz, 1 H), 8.76 (d, J=2.3 Hz, 1 H), 8.50 (dd, J=9.3, 2.3 Hz, 1 H), 8.21 (d, J=2.3 Hz, 1 H), 7.96 (d, J=9.3 Hz, 1 H), 7.44 (dd, J=8.8, 2.3 Hz, 1 H), 4.51 (br d, J=12.9 Hz, 2 H), 4.11 (q, J=7.1 Hz, 2 H), 3.68-3.56 (comp, 2 H), 3.34-3.26 (comp, 2 H), 2.92-2.82 (m, 1 H), 2.62 (t, J=5.7 Hz, 2 H), 2.18-2.08 (comp, 2H), 1.98-1.82 (comp, 2 H), 1.22 (t, J=7.1 Hz, 2 H). ESI-LCMS m/z calcd for C₂₈H₂₆ClN₅O₇: 579.15; found 578.0 (M−1)⁻.

Example 36 (Compound No. 114)

Preparation of 1-{6-Amino-2-[3-(3-carboxy-propionyl)-5-chloro-indol-1-yl]-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester

This compound was prepared in a manner analogous to that set forth in example C, except 2-amino-5-nitro-benzonitrile was used instead of 2-amino-5-bromo-benzonitrile in step 1, piperidine-4-carboxylic acid ethyl ester was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6. Step 6 product was reacted with hydrogen over palladium and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 1-{6-amino-2-[3-(3-carboxy-propionyl)-5-chloro-indol-1-yl]-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester as a yellow solid: R_f 0.24 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.14 (s, 1 H), 8.90 (d, J=9.1 Hz, 1 H), 8.24 (d, J=2.3 Hz, 1 H), 7.79 (d, J=8.8 Hz, 1 H), 7.47-7.40 (comp, 3 H), 4.31 (br d, J=13.8 Hz, 2 H), 4.11 (q, J=7.0 Hz, 2 H), 3.38-3.25 (comp, 4 H), 2.85-2.70 (m, 1 H), 2.62 (t, J=6.3 Hz, 2 H), 2.15-2.05 (comp, 2H), 1.95-1.80 (comp, 2 H), 1.22 (t, J=7.0 Hz, 3 H). ESI-LCMS m/z calcd for C₂₈H₂₈ClN₅O₅: 549.18; found 550.0 (M+1)⁺.

Example 37 (Compound No. 115)

Preparation of 4-[1-(6-Amino-4-morpholin-4-yl-quinazolin-2-yl)-5-chloro-1H-indol-3-yl]-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 2-amino-5-nitro-benzonitrile was used instead of 2-amino-5-bromo-benzonitrile in step 1, morpholine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6. Step 6 product was reacted with hydrogen over palladium and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-[1-(6-amino-4-morpholin-4-yl-quinazolin-2-yl)-5-chloro-1H-indol-3-yl]-4-oxo-butyric acid as a brown solid: R_f 0.19 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.14 (s, 1 H), 8.84 (d, J=9.1 Hz, 1 H), 8.24 (d, J=2.2 Hz, 1 H), 7.82 (br d, J=8.8 Hz, 1 H), 7.60-7.46 (comp, 2 H), 7.43 (dd, J=9.1, 2.2 Hz, 2 H), 3.92-3.80 (comp, 8 H), 3.28 (t, J=6.4 Hz, 2 H), 2.62 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₂₄H₂₂ClN₅O₄: 479.14; found 480.3 (M+1)⁺.

Example 38 (Compound No. 82)

Preparation of 1-[2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-(2-oxo-pyrrolidin-1-yl)-quinazolin-4-yl]-piperidine-4-carboxylic acid ethyl ester

This compound was prepared in a manner analogous to that set forth in example C, except piperidine-4-carboxylic acid ethyl ester and 6-bromo-2,4-dichloroquinazoline were used instead of p-anisidine and 2,4-dichloro-6-furan-2-yl-quinazoline in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6. Step 6 product was reacted with pyrrolidine and 4,5-bis(diphenylphosphino-9,9-dimethylxanthine (Xantphos) over Pd₂(dba)₃ in toluene at 100° C. and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 1-[2-[3-(3-carboxy-propionyl)-5-chloro-indol-1-yl]-6-(2-oxo-pyrrolidin-1-yl)-quinazolin-4-yl]-piperidine-4-carboxylic acid ethyl ester as a tan solid (0.011 g, 42%): R_f 0.29 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.17 (s, 1 H), 8.80 (d, J=8.8 Hz, 1 H), 8.40 (d, J=2.2 Hz, 1 H), 8.25 (d, J=2.3 Hz, 1 H), 8.08 (dd, J=9.1, 2.2 Hz, 1 H), 7.91 (d, J=9.1 Hz, 1 H), 7.45 (dd, J=8.8, 2.3 Hz, 1 H), 4.42 (br d, J=14.1 Hz, 2 H), 4.11 (q, J=7.1 Hz, 2 H), 3.98 (t, J=6.9 Hz, 2 H), 3.49-3.25 (comp, 4 H), 2.85-2.75 (m, 1 H), 2.65-2.54 (comp, 4 H), 2.15-2.05 (comp, 4 H), 1.95-1.80 (comp, 2 H), 1.22 (t, J=7.1 Hz, 3 H). ESI-LCMS m/z calcd for C₃₂H₃₂ClN₅O₆: 617.2; found 618.0 (M+1)⁺.

Example 39 (Compound No. 116)

Preparation of 4-{5-Chloro-1-[4-(4-methoxy-benzylamino)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 2-amino-5-trifluoromethylbenzonitrile was used instead of 2-amino-5-bromo-benzonitrile in step 1, 4-methoxybenzyl amine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[4-(4-methoxy-benzylamino)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a tan solid: R_f 0.67 (CH₂Cl₂/MeOH, 12:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.66 (br t, J=5.3 Hz, 1 H), 9.07 (s, 1 H), 8.85-8.80 (comp, 2 H), 8.18 (d, J=2.6 Hz, 1 H), 8.04 (dd, J=8.8, 2.6 Hz, 1 H), 7.91 (d, J=8.8 Hz, 1 H), 7.43 (d, J=8.6 Hz, 2 H), 7.34 (dd, J=9.1, 2.3 Hz, 1 H), 6.93 (d, J=8.6 Hz, 2 H), 6.67 (dd, J=3.2, 1.7 Hz, 1 H), 4.82 (br d, J=5.3 Hz, 2 H), 3.69 (s, 3 H), 3.27 (t, J=6.4 Hz, 2 H), 2.64 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₂₉H₂₂ClF₃N₄O₄: 582.13; found 583.3 (M+1)⁺.

Example 40 (Compound No. 83)

Preparation of 4-{5-Chloro-1-[4-(4-hydroxy-piperidin-1-yl)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 2-amino-5-trifluoromethylbenzonitrile was used instead of 2-amino-5-bromo-benzonitrile in step 1,4-hydroxypiperidine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6 and step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[4-(4-hydroxy-piperidin-1-yl)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as an orange solid: R_f 0.23 (CH₂Cl₂/MeOH, 12:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.14 (s, 1 H), 8.89 (d, J=8.9 Hz, 1 H), 8.21 (s, 2 H), 8.04 (1/2AB, J=9.1 Hz, 1 H), 8.03 (1/2AB, J=9.1 Hz, 1 H),7.42 (d, J=8.9 Hz, 1 H), 4.91 (d, J=8.9 Hz, 1 H), 4.28-4.19 (comp, 2 H), 3.96-3.86 (m, 1 H), 3.76-3.64 (comp, 2 H), 3.28 (t, J=6.9 Hz, 2 H), 2.62 (t, J=6.9 Hz, 2 H), 2.08-1.98 (comp, 2 H), 1.74-1.60 (comp, 2 H). ESI-LCMS m/z calcd for C₂₆H₂₂ClF₃N₄O₄: 546.13; found 569.3 (M+Na+1)⁺.

Example 41 (Compound No. 84)

Preparation of 4-{5-Chloro-1-[4-(4-hydroxymethyl-piperidin-1-yl)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example C, except 2-amino-5-trifluoromethylbenzonitrile was used instead of 2-amino-5-bromo-benzonitrile in step 1, 4-hydroxymethylpiperidine was used instead of p-anisidine in step 5 and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester was used instead of 4-(5-bromo-1H-indol-3-yl)-4-oxo-butyric acid methyl ester in step 6. Step 7 was replaced by treatment of trimethylsilanyl-ethyl ester with TBAF and 1 N HCl to provide 4-{5-chloro-1-[4-(4-hydroxymethyl-piperidin-1-yl)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a yellow solid: R_f 0.36 (CH₂Cl₂/MeOH, 12:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 9.10 (s, 1 H), 8.86 (d, J=9.0 Hz, 1 H), 8.20-8.15 (comp, 2 H), 8.02 (1/2AB, J=8.8 Hz, 1 H), 8.01 (1/2AB, J=8.8 Hz, 1 H),7.40 (dd, J=9.0, 2.3 Hz, 1 H), 4.60-4.46 (comp, 3 H), 3.47-3.24 (comp, 6 H), 2.62 (t, J=6.3 Hz, 2 H), 2.00-1.80 (comp, 3 H), 1.56-1.38 (comp, 2 H). ESI-LCMS m/z calcd for C₂₇H₂₄ClF₃N₄O₄: 560.14; found 583.3 (M+Na+1)⁺.

Example 42 (Compound No. 117)

Preparation of 4-{5-Chloro-1-[4-(4-methoxy-phenylamino)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was prepared in a manner analogous to that set forth in example X, except 4-{5-chloro-1-[4-(4-methoxy-phenylamino)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester (0.100 g, 0.150 mmol) was used instead of xxxxx to provide 4-{5-chloro-1-[4-(4-methoxy-phenylamino)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid as a yellow solid (0.065, 76%): R_f 0.20 (CH₂Cl₂/MeOH, 19:1, v/v) ¹H NMR (DMSO-d₆, 300 MHz) δ 10.52 (s, 1 H), 8.95 (s, 1 H), 8.93 (s, 1 H), 8.58 (d, J=9.0 Hz, 1 H), 8.12 (d, J=2.0 Hz, 1 H), 8.06 (dd, J=8.7, 2.0 Hz, 1 H), 7.91 (d, J=8.7 Hz, 1 H), 7.62 (d, J=8.9 Hz, 2 H), 7.15 (dd, J=9.0, 2.2 Hz, 1 H), 7.09 (d, J=8.9 Hz, 2 H), 3.84 (s, 3 H), 3.15 (t, J=6.4 Hz, 2 H), 2.60 (t, J=6.4 Hz, 2 H). ESI-LCMS m/z calcd for C₂₈H₂₀ClF₃N₄O₄: 568.11; found 569.3 (M+1)⁺.

Example 43 (Compound No. 118)

2-Chloro-4,6-diphenylpyrimidine

A mixture of 2,4,6-Trichloropyrimidine, 2.76 g (15.0 mmol), phenylboronic acid, 3.66 g (30.0 mmol), Pd(OAc)₂, 86 mg (0.38 mmol), triphenylphosphine, 200 mg (0.76 mmol) in 150 mL of ethylene glycol dimethyl ether was heated to obtain a clear solution. To the solution was added 25 mL of 4.0M aq. Na₂CO₃. The reaction mixture was refluxed for 24 h at 70 □C. The mixture was cooled to room temperature and diluted with 100 mL ethyl acetate. The organic layer was washed with water (2×50 mL), sat. aq. NaCl (1×50 mL), and dried (MgSO₄). After the solution was concentrated, the residue was recrystallized with Et₂O-Heptane (1:3) to afford the desired product in 1.64 g (41%) as a pale yellow solid. ¹H NMR (CDCl₃): δ 8.15-8.12 (m, 4H), 8.02 (s, 1H), 7.57-7.51 (m, 6H).

Example 44 (Compound No. 119)

4-(5-Chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester

To a two-necked, round bottom flask equipped with an addition funnel containing 5 Å molecular sieves topped with a jacketed water condenser was added the known compound 4-(5-Chloro-1H-indol-3-yl)-4-oxo-butyric acid methyl ester, 32.0 g (0.12 mol), 2-trimethylsilanyl-ethanol, 51.8 mL (0.36 mol), and LiBr, 52.3 g (0.60 mol), and 500 mL of THF/CH₂Cl₂ (3:1). The mixture was stirred at reflux fro 24 h. The mixture was cooled to room temperature, concentrated to 200 mL, and diluted with 200 mL of EtOAc. The mixture was washed with water (3×300 mL), sat. aq. NaCl (2×300 mL), and dried (MgSO₄). After the solution was concentrated, the residue was recrystallized with CH₂Cl₂-Heptane (1:2) to afford the desired product in 27.6 g (65%) as an off-white solid. ¹H NMR (CDCl₃): δ 8.43 (s, 1H), 8.11 (d, 1H, J=2.3 Hz), 7.48 (d, 1H, J=9.3 Hz), 7.21 (dd, 1H, J=9.3, 2.3 Hz), 4.09 (dd, 2H, J=9.0, 9.0 Hz), 3.16 (t, 2H, J=7.2 Hz), 2.61 (t, 2H, J=7.2 Hz), 0.93 (dd, 2H, J=9.0, 9.0 Hz), 0.02 (s, 9H).

Example 45 (Compound No. 92)

4-[5-Chloro-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid

To a solution of 4-[5-chloro-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid 2-trimethylsilanylethyl ester, 160 mg (0.27 mmol), in 25 mL of CH₂Cl₂ under a nitrogen atmosphere was added trifluoroacetic acid, 1.04 mL (13.5 mmol). The solution was stirred at room temperature overnight. The solution was concentrated to dryness, diluted with toluene, and concentrated again. This concentration/dilution process was repeated three more times. The remaining residue was crystallized with acetone-heptane (1:2) to afford the desired product in 104 mg (80%) as a pale yellow solid. R_f 0.15 (50% EtOAc-heptane); ¹H NMR (DMSO-d₆): δ 9.43 (s, 1H), 8.91 (d, 1H, J=10.0 Hz), 8.61 (s, 1H), 8.55-8.52 (m, 3H), 8.31 (d, 1H, J=2.3 Hz), 7.68-7.66 (m, 5H), 7.56 (dd, 1H, J=10.0, 2.3 Hz), 3.39 (t, 2H, J=6.3 Hz), 2.67 (t, 2H, J=6.3 Hz). LCMS m/z calcd for C₂₈H₂₀ClN₃O₃: 481.1 found 481.4 (M+1).

Example 46 (Compound No. 97)

4-[5-Chloro-1-(4-phenyl-6-phenylamino-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid

This compound was synthesized as reported previously, starting with aniline instead of phenylboronic acid to afford 4-[5-chloro-1-(4-phenyl-6-phenylamino-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid. R_f 0.29 (50% EtOAc-heptane); ¹H NMR (DMSO-d₆): δ 10.1 (s, 1H), 9.16 (s, 1H), 8.76 (d, 1H, J=9.7 Hz), 8.24 (d, 1H, J=2.3 Hz), 8.16-8.12 (m, 2H), 7.92 (s, 1H), 7.66-7.57 (m, 4H), 7.44 (t, 2H, J=8.7), 7.36 (dd, 1H, J=9.7, 2.3 Hz), 3.39 (t, 2H, J=6.3 Hz), 2.60 (t, 2H, J=6.3 Hz). LCMS m/z calcd for C₂₈H₂₁ClN₄O₃: 496.1 found 497.3 (M+1).

Example 47 (Compound No. 121)

4-[5-Chloro-1-(2,6-diphenyl-pyrimidin-4-yl)-1H-indol-3-yl]-4-oxo-butyric acid

This compound was synthesized as reported previously, starting with 4,6-dichloro-2-phenylpyrimidine, phenylboronic acid, and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid methyl ester to afford 4-[5-chloro-1-(2,6-diphenyl-pyrimidin-4-yl)-1H-indol-3-yl]-4-oxo-butyric acid. R_f 0.10 (50% EtOAc-heptane); ¹H NMR (DMSO-d₆): δ 9.45 (s, 1H), 8.84 (d, 1H, J=10.0 Hz), 8.59-8.56 (m, 2H), 8.51-8.48 (m, 3H), 8.29 (d, 1H, J=2.3 Hz), 7.65-7.62 (m, 6H), 7.55 (dd, 1H, J=10.0, 2.3 Hz), 3.39 (t, 2H, J=6.3 Hz), 2.60 (t, 2H, J=6.3 Hz). LCMS m/z calcd for C₂₈H₂₀ClN₃O₃: 481.1 found 482.5 (M+1).

Example 48 (Compound No. 99)

4-{5-Chloro-1-[5-(4-chloro-phenyl)-pyrimidin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid

This compound was synthesized as reported previously, starting with 2-chloro-5-(4-chloro-phenyl)-pyrimidine and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid methyl ester to afford 4-{5-chloro-1-[5-(4-chloro-phenyl)-pyrimidin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid. R_f 0.15 (50% EtOAc-heptane); ¹H NMR (DMSO-d₆): δ 9.28 (s, 2H), 9.19 (s, 1H), 8.78 (d, 1H, J=9.7 Hz), 8.25 (d, 1H, J=2.3 Hz), 7.91 (d, 2H, J=9.3 Hz), 7.62 (d, 2H, J=9.3 Hz), 7.49 (dd, 1H, J=9.7, 2.3 Hz), 3.29 (t, 2H, J=6.3 Hz), 2.60 (t, 2H, J=6.3 Hz). LCMS m/z calcd for C₂₂H₁₅Cl₂N₃O₃: 439.1 found 440.0 (M+1)

Example 49 (Compound No. 122)

4-[5-Chloro-1-(3-cyano-4,6-diphenyl-pyridin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid

This compound was synthesized as reported previously, starting with the commercially available 2-chloro-3-cyano-4,6-diphenyl-pyridine and 4-(5-chloro-1H-indol-3-yl)-4-oxo-butyric acid methyl ester to afford 4-[5-chloro-1-(3-cyano-4,6-diphenyl-pyridin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid. R_f 0.79 (100% EtOAc); ¹H NMR (DMSO-d₆) 9.19 (s, 1H), 8.40 (s, 1H), 8.32-8.27 (m, 3H), 7.96-7.88 (m, 3H), 7.66-7.63 (m, 3H), 7.58-7.54 (m, 3H), 7.44 (dd, 1H, J=9.7, 2.7 Hz), 3.23 (t, 2H, J=6.3 Hz), 2.64 (t, 2H, J=6.3 Hz). LCMS m/z calcd for C₃₀H₂₀ClN₃O₃: 505.1 found 505.4 (M+1).

Methods for Measuring PTP1B Activity

The test compounds were evaluated for their in vitro inhibitory activity against recombinant human PTP1B with phosphotyrosyl dodecapeptide TRDI(P)YETD(P)Y(P)YRK. This corresponds to the 1142-1153 insulin receptor kinase regulatory domain, phosphorylated on the 1146, 1150 and 1151 tyrosine residues; IR-triphosphopeptide)as a source of substrate. Enzyme reaction progression was monitored via the release of inorganic phosphate as detected by the malachite green—ammonium molybdate method for the phosphopeptide.

All references disclosed herein are hereby incorporated by reference for all purposes.

The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the invention and that modifications may be made therein without departing from the spirit or scope of the invention.

Claims

1. A compound of the formula:

2. A compound according to claim 1 of the formula:

3. The compounds according to claim 2, wherein R10 is halogen, quinoxalinyl, dihydroquinoxalinonyl, piperazinyl, tetrahydroquinolinyl, dihydroquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, indolyl, or isoindolyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently selected from the group consisting of oxo, —C(O)—(C1-C6 alkyl)-C(O)—OR1, —C(O)—NH—(C1-C6 alkyl)-C(O)—OR1, —C(O)—(C1-C6 haloalkyl)-C(O)—OR1, C1-C6 haloalkenyl-C(O)—OR1, —SO2-(C1-C6 alkyl), —SO2-phenyl, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkoxycarbonyl, C2-C6 alkanoyl optionally substituted with CO2H or CO2—(C1-C4 alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, NO02, CF3 and OCF3, or CO2H.

4. The compounds according to claim 3 wherein R10 is chloro.

5. The compounds according to claim 3 wherein R10 is indolyl optionally substituted with one or two groups independently selected from halogen, —C(O)—(C1-C6 alkyl)-C(O)—OR1, —C(O)—NH—(C1-C6 alkyl)-C(O)—OR1, —C(O)—(C1-C6 haloalkyl)-C(O)—OR1, C1-C6 haloalkenyl-C(O)—OR1.

6. The compounds according to claim 5 wherein the halogen is bromo or chloro.

7. The compounds according to claim 5 wherein R1 is —H and the C1-C6 alkyl is —C2H4— or —CH2—.

7. The compounds according to claim 5 wherein C1-C6 haloalkyl is —CF2—.

8. The compounds according to claim 5 wherein C1-C6 haloalkenyl is —CH═CF—.

9. The compounds according to claim 2, wherein each R3 is independently C1-C6 alkyl, halogen, —CN, C1-C6-alkoxy, —(C1-C4 alkoxy)-phenyl; and each R4 is independently halogen, or furanyl.

10. The compounds according to claim 2, wherein R10 is quinoxalinonyl, piperazinyl, tetrahydroquinolinyl, dihydroquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, or indol-1-yl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently selected from the group consisting of —C(O)—C2H4—C(O)—OH, —C(O)—NH—C2H4—C(O)—OH, —SO2—(C1-C6 alkyl), —SO2-phenyl, halogen, C1-C4 alkyl, C1-C4 alkoxy, C4 alkoxycarbonyl, C2-C6 alkanoyl optionally substituted with CO2H or CO2—(C1-C4 alkyl), phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, NO2, CF3 and OCF3, and CO2H; each R3 is independently C1-C6 alkyl, halogen, or benzyloxy; and each R4 is independently halogen.

11. The compounds according to claim 3, wherein R10 is indol-1-yl, indol-2-yl, isoindol-1-yl, or isoindol-2-yl, each of which is optionally substituted with 1 or 2 groups that are independently —SO2—(C1-C6 alkyl), —SO2-phenyl, halogen, C1-C4 alkyl, C1-C4 alkoxy, C4 alkoxycarbonyl, C2-C6 alkanoyl optionally substituted with CO2H or CO2—(C1-C4 alkyl), or phenyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, NO2, CF3 and OCF3, or CO2H; each R3 is independently C1-C6 alkyl, halogen, or benzyloxy; and each R4 is independently halogen.

12. The compounds according to claim 11, wherein R10 is indol-1-yl or isoindol-2-yl, each of which is optionally substituted with 1 or 2 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, C4 alkoxycarbonyl, or C2-C6 alkanoyl optionally substituted with CO2H or CO2—(C1-C4 alkyl); each R3 is independently C1-C6 alkyl, halogen, or benzyloxy; and each R4 is independently halogen.

13. The compounds according to claim 12, wherein R10 is indol-1-yl substituted with 1 or 2 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, or C2-C4 alkanoyl optionally substituted with CO2H or CO2—(C1-C4 alkyl).

14. The compounds according to claim 12, wherein R10 is indol-1-yl substituted with 1 or 2 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, or C2-C4 alkanoyl optionally substituted with CO2H or CO2—(C1-C4 alkyl), where at least one group is an optionally substituted C2-C4 alkanoyl in the 3-position of the indole ring.

15. A compound according to claim 1 of the formula

16. The compounds according to claim 15, wherein m is 0, 1, or 2; n is 0, 1, or 2; p is 0, 1, or 2; each R11 is independently —SO2NR5R6, —SO2CF3, —SO2(C1-C6 alkyl), alkoxy, thioalkoxy, alkyl, haloalkyl, —SO2(C1-C6 haloalkyl), OCF3, SCF3, —NR7R8, C2-C6 alkanoyl, NO2, or C1-C6 alkoxycarbonyl.

17. The compounds according to claim 16, wherein each R3 is independently C1-C6 alkyl, halogen, —(C1-C4 alkoxy)-phenyl; and each R4 is independently halogen, or furan.

18. The compounds according to claim 17, wherein n is 1 or 2; R1 is H or C2-C6 alkanoyl; and at least one of the R11 groups is —SO2NR5R6.

19. The compounds according to claim 15, wherein n is 1 or 2; and one of the R11 groups is —C(O)R9, wherein R9 is independently phenyl, piperidinyl, pyrrolidinyl, morpholinyl, —NH-phenyl, or —N(C1-C6 alkyl)-phenyl, wherein the phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently, halogen, C1-C6 alkyl, NO2, or C1-C6 alkoxy.

20. The compounds according to claim 15, of the formula:

21. The compounds according to claim 20, wherein the R4 group is attached to position 6, of the quinazolinyl ring; and R3 is H, C1-C6 alkyl, halogen, or benzyloxy.

22. The compounds according to claim 15, wherein m is 0, 1, or 2; n is 0, 1, or 2; p is 0, 1, or 2; and each R11 is independently —SO2NR5R6, —SO2CF3, —SO2(C1-C6 alkyl), alkoxy, thioalkoxy, alkyl, haloalkyl, —SO2(C1-C6 haloalkyl), OCF3, SCF3, —NR7R8, C2-C6 alkanoyl, NO2, or C1-C6 alkoxycarbonyl.

23. The compounds according to claim 15, wherein each R3 is independently C1-C6 alkyl, halogen, —(C1-C4 alkoxy)-phenyl; and each R4 is independently halogen or furanyl.

24. The compounds according to claim 15, wherein n is 1 or 2; R1 is H or C2-C6 alkanoyl; and at least one of the R11 groups is —SO2NR5R6.

25. The compounds according to claim 15, wherein m is 1; the R4 group is attached to position 6 of the quinazolinyl ring; and R3 is H, C1-C6 alkyl, halogen, or benzyloxy.

26. The compounds according to claim 25, where R4 is furanyl.

27. The compounds according to claim 26, where R4 is halogen.

28. A compound according to claim 1 of the formula:

29. The compounds according to claim 28 of the formula

30. The compounds according to claim 29 wherein L is a bond.

31. The compounds according to claim 30 wherein R3 is phenyl substituted with ethyl or methoxy.

32. The compounds according to claim 31 wherein R4 is phenyl substituted chloro or fluoro.

32. A compound according to claim 1 of the formula:

33. The compounds according to claim 32 of the formula

34. The compounds according to claim 33 wherein L is a bond and R3 and R4 is aryl substituted with C1-C6-alkoxy.

35. The compounds according to claim 34 wherein R3 and R4 are phenyl substituted with methoxy.

36. The compounds according to claim 35 wherein R10 is heteroaryl substituted with two groups that are C(O)—(C1-C6 alkyl)-C(O)—OR1 or halogen.

37. The compounds according to claim 36 wherein R10 is indolyl.

38. The compounds according to claim 37 one substituent of R10 is halogen and the other is C(O)—(C1-C6 alkyl)-C(O)—OR1.

39. The compounds according to claim 38 wherein R1 is —H or —(C1-C5 alkyl)-Si(C1-C5 alkyl)3.

40. The compounds according to claim 38 wherein R1—C2H5—Si—(CH3)3.

41. The compounds according to claim 38 wherein halogen is chloro or bromo.

42. A compound according to claim 1 of the formula:

43. The compounds according to claim 42 of the formula

44. The compounds according to claim 43 wherein R4 is heterocycloalkyl and R3 is heterocycloakyl or aryl substituted with C1-C6 alkyl.

45. The compounds according to claim 44 wherein R4 is morpholino or pyrrolidinyl.

46. The compounds according to claim 44 wherein R3 is dihydroquinolinyl or phenyl substituted with tert-butyl.

47. The compounds according to claim 44 wherein R10 is heteroaryl substituted with 2 groups.

48. The compounds according to claim 47 wherein R10 is indolyl.

49. The compounds according to claim 48 wherein one substituent is C(O)—(C1-C6 alkyl)-C(O)—OR1 and the other is halogen.

50. The compounds according to claim 49 wherein R1 is —H and halogen is chloro or bromo.

51. A compound according to claim 1 which is 4-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-benzenesulfonamide; 2-({4-[(6-Bromo-4-phenyl-quinazolin-2-yl)-carboxymethyl-amino]-benzenesulfonyl}-methyl-amino)-3-phenyl-propionic acid; (6-Bromo-4-phenyl-quinazolin-2-yl)-(4-trifluoromethylsulfanyl-phenyl)-amine; (6-Bromo-4-phenyl-quinazolin-2-yl)-(4-trifluoromethanesulfonyl-phenyl)-amine; 4-(6-Chloro-4-phenyl-quinazolin-2-yl)-3,4-dihydro-1H-quinoxalin-2-one; 6-chloro-N-(1,1-dioxido-1-benzothien-6-yl)-4-phenylquinazolin-2-amine; 4-(6-Furan-2-yl-4-phenyl-quinazolin-2-ylamino)-benzenesulfonamide; 4-(6-Bromo-4-phenyl-quinazolin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester; 4-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-N-(2,6-dimethyl-phenyl)-benzamide; 4-[4-(4-Butyl-phenyl)-6-furan-2-yl-quinazolin-2-ylamino]-benzenesulfonamide; 4-(4-Benzyloxy-phenyl)-6-bromo-2-chloro-quinazoline; 2-(4-Benzenesulfonyl-piperazin-1-yl)-6-chloro-4-phenyl-quinazoline; 6-Chloro-2-(3,4-dihydro-2H-quinolin-1-yl)-4-(4-ethyl-phenyl)-quinazoline; 6-Chloro-2-[4-(4-nitro-phenyl)-piperazin-1-yl]-4-phenyl-quinazoline; 4-[1-(6-Chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-{5-Bromo-1-[4-(4-butyl-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 3-[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-2,2-difluoro-3-oxo-propionic acid; 3-[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-2-fluoro-acrylic acid; 4-{5-Bromo-1-[4-(1-carboxy-2-phenyl-ethylamino)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperazine-1-carboxylic acid tert-butyl ester; 1-{4-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-7-furan-2-yl-quinazolin-2-yl}-piperidine-4-carboxylic acid ethyl ester; 4-{1-[4-(4-tert-Butyl-phenylamino)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-5-chloro-1H-indol-3-yl}-4-oxo-butyric acid; 4-{1-[4,6-Bis-(3-methoxy-phenyl)-pyrimidin-2-yl]-5-bromo-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Bromo-1-[4-(3,4-dihydro-2H-quinolin-1-yl)-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(4-chloro-phenyl)-5-(4-ethyl-phenyl)-thiazol-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Chloro-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid 2-trimethylsilanylethyl ester; 4-(6-Chloro-4-phenyl-quinazolin-2-ylamino)-benzenesulfonamide; 4-[4-(4-tert-Butyl-phenyl)-quinazolin-2-ylamino]-benzenesulfonamide; 2-{[4-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-benzenesulfonyl]-methyl-amino}-3-phenyl-propionic acid; [(6-Bromo-4-phenyl-quinazolin-2-yl)-(4-sulfamoyl-phenyl)-amino]-acetic acid; 2-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-benzenesulfonamide; 4-[(6-Bromo-4-phenyl-quinazolin-2-yl)-(4-sulfamoyl-phenyl)-amino]-butyric acid; 3-(6-Bromo-4phenyl-quinazolin-2-ylamino)-benzenesulfonamide; N-[4-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-phenyl]-acetamide; 1-[4-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-phenyl]-ethanone; [3-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-phenyl]-piperidin-1-yl-methanone; [3-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-phenyl]-morpholin-4-yl-methanone; (6-Chloro-4-phenyl-quinazolin-2-yl)-(4-nitro-phenyl)-amine; 2-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-3-phenyl-propionic acid; 2-[6-Bromo-4-(4-butyl-phenyl)-quinazolin-2-ylamino]-benzenesulfonamide; 4-(6-Chloro-4-phenyl-quinazolin-2-ylamino)-benzoic acid methyl ester; N-(2,4-Dimethyl-phenyl)-4-(6-methyl-4-phenyl-quinazolin-2-ylamino)-benzamide; [4-(6-Bromo-4-phenyl-quinazolin-2-ylamino)-phenyl]-piperidin-1-yl-methanone; (6-Bromo-4-phenyl-quinazolin-2-yl)-(4-nitro-phenyl)-amine; (6-Bromo-4-phenyl-quinazolin-2-yl)-(2-methyl-5-nitro-phenyl)-amine; [6-Chloro-4-(4-ethyl-phenyl)-quinazolin-2-yl]-(4-nitro-phenyl)-amine; (6-Chloro-4-phenyl-quinazolin-2-yl)-(2-nitro-phenyl)-amine; 2-(6-Furan-2-yl-4-phenyl-quinazolin-2-ylamino)-benzenesulfonamide; [(6-Chloro-4-phenyl-quinazolin-2-yl)-(2-nitro-phenyl)-amino]-acetic acid ethyl ester; 1-(6-Chloro-4-phenyl-quinazolin-2-yl)-1H-indole-5-carboxylic acid methyl ester; 4-[5-Bromo-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Bromo-1-(6-fluoro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-{1-[6-Bromo-4-(2-fluoro-phenyl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-phenyl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Bromo-1-[4-(4-cyano-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Bromo-1-[4-(4-fluoro-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[1-(6-Chloro-4-phenyl-quinazolin-2-yl)-6-fluoro-1H-indol-3-yl]-4-oxo-butyric acid; 4-[1-(6-Furan-2-yl-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Bromo-1-(6-furan-2-yl-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-{1-[4-(4-Butyl-phenyl)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Bromo-1-(6-chloro-4-phenyl-quinolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Bromo-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-hydroxy-butyric acid; {[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indole-3-carbonyl]-amino}-acetic acid; 3-(3-Carboxy-propionyl)-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indole-5-carboxylic acid methyl ester; 4-[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-N-hydroxy-4-oxo-butyramide; 3-{[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indole-3-carbonyl]-amino}-propionic acid; 3-[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-3-hydroxy-propionic acid; 3-[5-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-3-oxo-propionic acid; 4-[6-Chloro-1-(6-chloro-4-phenyl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-phenylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Bromo-1-[6-furan-2-yl-4-(4-methoxy-benzylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-(5-Bromo-1-{6-furan-2-yl-4-[(furan-2-ylmethyl)-amino]-quinazolin-2-yl}-1H-indol-3-yl)-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(4-fluoro-benzylamino)-6-furan-2-yl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Chloro-1-(6-furan-2-yl-4-pyridin-2-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-(5-Chloro-1-{6-furan-2-yl-4-[(pyridin-4-ylmethyl)-amino]-quinazolin-2-yl}-1H-indol-3-yl)-4-oxo-butyric acid; 4-{5-Chloro-1-[6,7-dimethoxy-4-(4-methoxy-benzylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Bromo-1-(6-furan-2-yl-4-morpholin-4-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 1-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid; 1-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester; 1-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid; 1-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester; 4-[5-Chloro-1-(6-furan-2-yl-4-morpholin-4-yl-quinazolin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 1-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-nitro-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester; 4-{5-Chloro-1-[6-furan-2-yl-4-(4-hydroxy-piperidin-1-yl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 1-[2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-(2-oxo-pyrrolidin-1-yl)-quinazolin-4-yl]-piperidine-4-carboxylic acid ethyl ester; 4-{5-Chloro-1-[4-(4-hydroxy-piperidin-1-yl)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(4-hydroxymethyl-piperidin-1-yl)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 2-{2-[5-Bromo-3-(3-carboxy-propionyl)-indol-1-yl]-6-furan-2-yl-quinazolin-4-ylamino}-butyric acid; 2-{2-[3-(3-Carboxy-propionyl)-5-chloro-indol-1-yl]-6-furan-2-yl-quinazolin-4-ylamino}-butyric acid; 4-{5-Chloro-1-[6-furan-2-yl-4-(2-methanesulfonyl-ethylamino)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{1-[4-(Carbamoylmethyl-amino)-6-furan-2-yl-quinazolin-2-yl]-5-chloro-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Cyano-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Chloro-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[6-Chloro-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Bromo-1-(4,6-diphenyl-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(3-methoxy-phenyl)-6-phenyl-pyrimidin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Chloro-1-(4-phenyl-6-phenylamino-pyrimidin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-{5-Chloro-1-[6-(4-chloro-phenyl)-2-phenyl-pyrimidin-4-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[5-(4-chloro-phenyl)-pyrimidin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(dibenzofuran-4-ylamino)-benzyl]-1H-indol-3-yl)-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(2-methoxy-dibenzofuran-3-ylamino)-benzyl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Chloro-1-(4-thianthren-1-yl-benzyl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Chloro-1-(4-dibenzofuran-4-yl-benzyl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Chloro-1-(4-dibenzothiophen-4-yl-benzyl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(4-chloro-phenyl)-5-(4-methoxy-phenyl)-thiazol-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(4-fluoro-phenyl)-5-(4-methoxy-phenyl)-thiazol-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[2-oxo-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethyl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[2-(5-chloro-3-methyl-benzo[b]thiophen-2-yl)-2-oxo-ethyl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-[5-Bromo-1-(6-furan-2-yl-4-hydroxy-quinazolin-2-yl]-1H-indole-3-yl]-4-oxo-butyric acid; 4-(5-Bromo-1-{6-furan-2-yl-4-[(furan-2-ylmethyl)-amino]-quinazolin-2-yl}-1H-indole-3-yl)-4-oxo-butyric acid; 4-{5-Chloro-1-[6-furan-2-yl-4-(4-hydroxymethyl-piperidin-1-yl)-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-(5-Chloro-1-{4-[(furan-2-ylmethyl)-amino]-6,7-dimethoxy-quinazolin-2-yl}-1H-indol-3-yl)-4-oxo-butyric acid; 1-{6-Amino-2-[3-(3-carboxy-propionyl)-5-chloro-indol-1-yl]-quinazolin-4-yl}-piperidine-4-carboxylic acid ethyl ester; 4-[1-(6-Amino-4-morpholin-4-yl-quinazolin-2-yl)-5-chloro-1H-indol-3-yl]-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(4-methoxy-benzylamino)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 4-{5-Chloro-1-[4-(4-methoxy-phenylamino)-6-trifluoromethyl-quinazolin-2-yl]-1H-indol-3-yl}-4-oxo-butyric acid; 2-Chloro-4,6-diphenylpyrimidine; 4-(5-Chloro-1H-indol-3-yl)-4-oxo-butyric acid 2-trimethylsilanyl-ethyl ester; 4-[5-Chloro-1-(2,6-diphenyl-pyrimidin-4-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 4-[5-Chloro-1-(3-cyano-4,6-diphenyl-pyridin-2-yl)-1H-indol-3-yl]-4-oxo-butyric acid; 2-[4-(4-Butyl-phenyl)-6-furan-2-yl-quinazolin-2-ylamino]-benzenesulfonamide; or a pharmaceutically acceptable salt thereof.

52. A method of treating diabetes comprising administering to a patient in need thereof, a pharmaceutically acceptable amount of a compound or salt according to claim 1.

53. A pharmaceutical composition of a compound or salt of claim 1 and at least one pharmaceutically acceptable solvent, carrier, adjuvant or excipient.